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Abstract
The identification of promising drug candidates is a major milestone in the early
stages of drug discovery and design. Among the properties that have to be op-
timized before a drug candidate is admitted to clinical testing, potency and tar-
get selectivity are of great interest and can be addressed very early. Unfortu-
nately, optimization–relevant knowledge is often limited, and the analysis of noisy
and heterogeneous biological screening data with standard methods like QSAR is
hardly feasible. Furthermore, the identification of compounds displaying different
selectivity patterns against related targets is a prerequisite for chemical genet-
ics and genomics applications, allowing to specifically interfere with functions of
individual members of protein families. In this thesis it is shown that computa-
tional methods based on molecular similarity are suitable tools for the analysis
of compound potency and target selectivity. Originally developed to facilitate
the efficient discovery of active compounds by means of virtual screening of com-
pound libraries, these ligand–based approaches assume that similar molecules are
likely to exhibit similar properties and biological activities based on the similarity
property principle. Given their holistic approach to molecular similarity analysis,
ligand–based virtual screening methods can be applied when little or no structure–
activity information is available and do not require the knowledge of the target
structure.
The methods under investigation cover a wide methodological spectrum and
only rely on properties derived from one– and two–dimensional molecular repre-
sentations, which renders them particularly useful for handling large compound
libraries. Using biological screening data, these virtual screening methods are
shown to be able to extrapolate from experimental data and preferentially de-
tect potent compounds. Subsequently, extensive benchmark calculations prove
that existing 2D molecular fingerprints and dynamic mapping algorithms are
suitable tools for the distinction between compounds with differential selectiv-
ity profiles. Finally, an advanced dynamic mapping algorithm is introduced that
is able to generate target–selective chemical reference spaces by adaptively iden-
tifying most–discriminative molecular properties from a set of active compounds.
These reference spaces are shown to be of great value for the generation of pre-
dictive target–selectivity models by screening a biologically annotated compound
library.
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Chapter 1
Introduction
Pharmaceutical research as well as chemical biology critically depend on the iden-
tification of small molecules that specifically bind to a target protein, thereby
affecting its biological activity in a desired manner. The main goal of chemical
biology is to explain the molecular and cellular functions of biological targets with
the help of small molecules (Stockwell [2004]). In this context, chemical genetics
(Alaimo et al. [2001]; Spring [2005]) seeks to elucidate specific molecular mech-
anisms by perturbing biological processes using small ligands, whereas chemical
genomics (Spring [2005], Bredel and Jacoby [2004]) systematically studies thera-
peutic target–ligand interactions on a large scale in order to identify new targets
and biologically active compounds (Bredel and Jacoby [2004]). However, the iden-
tification of small molecules that selectively bind to a given target has already long
been a major goal of drug design.
The Drug Design Process
In pharmaceutical research, the process of discovering or designing a new thera-
peutic agent can roughly be divided into three parts as indicated in Table 1.1. In
the beginning, possible therapeutic targets associated with a given disease, such
as receptors, enzymes, DNA, or RNA have to be identified. Then, small molecules
need to be found and optimized that specifically bind to a selected target and it
must be demonstrated, that this interaction leads to desired therapeutic effects.
Ultimately, such molecules might become clinical candidates. High–throughput–
screening (HTS) is a major source for the identification of new hits or leads. HTS
can process very large compound libraries in a relatively short period of time
thanks to progressing robotic automation and miniaturization. If it is possible
1
2Stage Steps
Drug discovery Target identification and validation
Lead identification and optimization
Preclinical studies Laboratory tests to determine the effects in vitro and
in vivo
Drug formulation and manufacturing
Clinical studies Multi–phase study of safety and effectiveness in humans
Table 1.1: Drug discovery and drug development process. Drug candidates have to pass
several stages to verify medicinal activity, effectiveness, and safety before being approved. The
entire process takes on average ten to 12 years.
to identify lead compounds1, they serve as a starting point for a successive op-
timization process aiming at the improvement of pharmacodynamic and –kinetic
properties such as potency, target–selectivity, and ADME2 properties. Drug can-
didates have to be thoroughly tested in vitro and then in non–human organisms in
vivo in order to verify their efficacy and safety. A new drug is finally approved if it
successfully passes at least three clinical trials that prove safety and effectiveness
in humans. As the pass through all stages is very time– and cost–intensive3, opti-
mization of the drug discovery and development process is of great importance. In
this context, it is believed that complementing high–throughput discovery tech-
nologies with computational approaches is necessary to increase the success rate
of drug discovery projects (Jorgensen [2004]; Bajorath [2002]). Thus, there is a
substantial interest in the development of computational tools that can aid in, for
example, the steps of lead identification and optimization.
Biological screening data obtained from early–stage HTS experiments present
a suitable starting point for computational analysis. Furthermore, methods for
virtual screening (VS) that are able to efficiently screen large compound databases
in silico and select a limited number of candidate structures for subsequent ex-
perimental testing complement HTS in a meaningful way (Bajorath [2002]).
1A lead is a prototypical structure with desired biological activity and selectivity (Bleicher
et al. [2003])
2Acronym for Absorption, Distribution, Metabolism, and Excretion
3DiMasi et al. [2003], report average pre–approval costs of US$ 802 million per new drug
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Analysis of High–Throughput Screening Data
In drug discovery, high–throughput screening is the most widely used approach
to rapidly test large amounts of compounds that potentially modulate a disease–
associated target (Macarron [2006]). Systematic methods for the efficient screen-
ing of compounds date back to the beginning of the last century when Paul Ehrlich
tested more than 600 compounds as possible drugs against syphilis (Ehrlich and
Bertheim [1912]). Although the scale of HTS campaigns has consistently increased
ever since, having currently arrived at a volume of between one and five millions
compounds per screen (Crisman et al. [2007]), the number of approved drugs per
year has almost remained constant over the last decade (Bajorath [2002]). This
is attributed in part to the approximate nature of HTS results, suffering from
a number of systematic difficulties (Good et al. [2000]; Bajorath [2002]; Bleicher
et al. [2003]). First of all, the activity threshold applied to distinguish active
from inactive compounds is often arbitrarily set, so that, depending on compound
library design and drugability4 of the target, detection of false–positives and false–
negatives is likely. Furthermore, Gao et al. [2002] discovered that the accuracy
of predictive models based on HTS data analysis is often impaired by boundary
effects that arise when compounds with activity close to the threshold are taken
into account. This is further rationalized by their finding that these compounds
are often more similar to each other than most and least potent hits. Additionally,
measurement errors can lead to an incorrect classification of compounds with an
activity close to the activity threshold of the assay. In general, biological screen-
ing data are noisy and prone to errors arising from different sources (Bajorath
[2002]). Non–specific binding events, off–target binding in cell–based assays, toxic
effects or promiscuous ligands, so called frequent hitters, are responsible for false–
positives while degradation of compounds on screening plates, limited purity and
low concentrations in compound mixtures can result in false–negatives. In the
case of compound mixtures special care has to be taken that pooled compounds
do not react in order to avoid flawed measurements.
Although differing in their conceptual origins, high–throughput and virtual
screening are highly complementary disciplines in modern early–phase drug dis-
covery programs. However, the success rate of discovery programs has not
scaled with the expanded efforts put into high–throughput technologies (Bajo-
rath [2002]). Today, it is increasingly recognized that a combination of experi-
4The feasibility of a target to be effectively modulated by a suitable drug candidate (Bleicher
et al. [2003])
4mental and computational methods early on is beneficial for the overall success
of drug discovery and design (Bajorath [2001a]). It has also been found that
compounds optimized for potency and selectivity might often not respond well to
subsequent modifications to further improve important biophysical, biochemical,
and ADME properties (Bleicher et al. [2003]). Therefore, computational filtering
of screening libraries to ensure drug–likeness in advance and/or in parallel to po-
tency and selectivity optimization is well suited to reduce the late–stage attrition
of drug candidates (Bajorath [2002]). This also means that the identification of
multiple hits with significant potency is highly desirable in order to facilitate the
parallel multi–property optimization. As has been shown by a number of studies
(Rusinko et al. [1999]; Jones-Hertzog et al. [1999]), virtual screening methods can
successfully be applied to analyze HTS data in order to generate predictive mod-
els of activity that can be used for further focused and/or sequential screening.
Once lead compounds are identified, quantitative structure–activity relationship
(QSAR) methods are applied to correlate structural features and properties of
molecules with their activity (Esposito et al. [2004]). The paradigm of QSAR
analysis is to suggest small structural modifications that significantly improve the
biological activity of test compounds. Therefore, QSAR analysis requires the pres-
ence of discontinuous structure–activity relationships (SARs), but exploring such
SARs is also prone to significant errors (Maggiora [2006]).
Given their whole–molecule perspective, methods based on molecular similar-
ity do not make any assumption about pharmacophores or parts of molecules that
render them biologically active (Bajorath [2002]) and can thus be applied when
little or no SAR information is available. Similarity methods require the presence
of continuous SARs, where departures from the structures of active compounds
cause gradual changes in biological activity, consistent with the similarity property
principle, stating that“similar molecules should have similar biological properties“
(Johnson and Maggiora [1990]). In contrast to QSAR analysis, similarity methods
usually do not take differences in compound potency into account. In addition,
the qualitative manner in which SARs are explored causes a limitation of sim-
ilarity methods: newly identified hits are generally much less potent than the
reference molecules because one deliberately departs from optimized structural
motifs (Bajorath [2002]).
Therefore, virtual screening methods that can be used for potency and se-
lectivity analysis and that additionally are able to cope with hit diversity are of
great interest. Importantly, the public availability of biological screening data as
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provided by PubChem5 or other initiatives presents a major opportunity for the
evaluation of such methods under realistic conditions (Vogt and Bajorath [2007];
Stumpfe et al. [2007]).
Virtual Screening
Computational methods for virtual screening of compound databases can be di-
vided into structure– and ligand–based approaches. Structure–based methods
(Shoichet [2004]) try to estimate how good a small molecule binds to a target
protein, for example by trying to dock it into the protein’s binding site. These
methods depend on the availability of three–dimensional protein structure in-
formation, whose prediction is in the spotlight of structural genomics. Also, a
detailed knowledge of the binding mode is required and affinity–scoring functions
remain a crucial issue of structure–based approaches like docking. However, meth-
ods that screen compounds by assessing their similarity to already known ligands
are still dominant in the field of virtual screening (Bajorath [2002]). The reason for
this is that information about known ligands that bind to the target or a closely
related one are often easier to obtain than knowledge of the three–dimensional
target structure (Bajorath [2001a]).
Aiming at the identification of novel active molecules, molecular similarity
analysis was introduced in the early 1990s, drawing upon the formulation of the
similarity property principle. Molecular similarity analysis captures information
about molecular structure and physicochemical features, like the solubility in po-
lar solvents, with the help of substructures and mathematical models that enable
the comparison of molecules and thus quantification of their similarity (Bajorath
[2001b]; Livingstone [2000]). Such mathematical models are termed molecular de-
scriptors. Since the beginning of molecular similarity analysis, literally thousands
of descriptors have been defined (Todeschini et al. [2000]). According to the type
of molecular representation from which they are derived, descriptors are often
classified as one–, two–, or three–dimensional. Table 1.2 shows three examples
of molecular representations of different dimensionality and provides examples
of molecular descriptors. The molecular formula gives the counts of all present
atoms and can thus be used, for example, to determine the molecular mass of the
molecule or detect the presence of certain elements. The two–dimensional molec-
ular structure can be represented intuitively in a molecular graph as shown in
5The PubChem Project
http://pubchem.ncbi.nlm.nih.gov
6Representation Descriptors
C8H10N4O2 −→
molecular weight: 194.2 u
number of heavy atoms: 14
−→
number of rings: 2
logP(o/w): -0.604
MACCS keys: 65, 77
−→ van der Waals volume: 175 A˚
3
van der Waals surface area: 203 A˚2
Table 1.2: Representations and molecular descriptors. Depicted are one–, two–, and
three–dimensional molecular representations together with several molecular descriptors. The
classification of descriptors is not always strict, for instance, molecular surfaces can also be
approximated from 2D representations. The highlighted substructures of the 2D molecular
graph correspond to the indicated MACCS keys, which account for the presence of structural
fragments, as discussed in the text.
Figure 1.2, where atoms correspond to nodes and bonds to edges. Alternatively,
SMILES and InChI strings (Weininger [1988]; Stein et al. [2003]) were designed
to encode the two–dimensional structure of a molecule in a one–dimensional char-
acter string. These representations permit the determination of two–dimensional
features as aromatic rings or connectivity patterns and physicochemical properties
like solubility. 3D descriptors are able to describe molecular properties such as the
van der Waals volume or the electrostatic interaction energy, that depend on the
conformation of a molecule in three–dimensional space. As another example, 3D
pharmacophores represent spatial arrangements of steric and electrostatic features
that are essential for bioactivity.
A survey of the spectrum of virtual screening methods is provided in Figure
1.1, ranging from 3D structure–based approaches like docking to 2D and 3D
ligand–based methods based on appropriate molecular representations and de-
scriptors. Ligand–based virtual screening (LBVS) methods can essentially be sep-
arated into two methodologically different approaches: similarity searching and
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3D LBVS
2D LBVS
Structure–based
Docking
Volume/surface matching
Pharmacophore matching
Substructure searching
2D fingerprints
(x1, x2,. . . ,xn−1, xn)
Searching in
unmodified descriptor spaces
Figure 1.1: Survey of virtual screening methods and tools. Virtual compound
databases can be screened by either docking compounds into the target’s binding
site or comparing them to known ligands. In ligand–based methods, two– and three–
dimensional representations can be used to determine molecular features like substruc-
tures, connectivity patterns or physicochemical properties that can be encoded and
employed for similarity analysis in various ways.
compound classification (Stahura and Bajorath [2005]). Methods used for simi-
larity searching calculate a quantitative measure of similarity of a compound to
one or more active compounds, termed template or reference compounds, whereas
classification methods assess compounds qualitatively with respect to the proper-
ties derived from a set of multiple templates. Crucial to all of these methods is
the appropriate choice of descriptors that constitute the chemical reference space
into which compounds are projected (Bajorath [2001b]; Agrafiotis et al. [2002]).
A widely followed scheme is the generation of low–dimensional and/or orthogo-
nal references spaces, thereby minimizing correlation between descriptors of the
8reference space that is generally believed to unfavorably bias similarity analysis.
Usually, generation of the reference space takes place before similarity analysis is
carried out, but for some methods like recursive partitioning and dynamic map-
ping algorithms (Friedman [1977]; Eckert et al. [2006]), as introduced later on,
chemical reference spaces are produced by the methods themselves. These meth-
ods are able to solve the descriptor–selection problem based on their ability to
assess descriptor specificity in the given experimental context.
Molecular fingerprints
Molecular fingerprints are widely used descriptors in molecular similarity searching
and encode information about the molecular structure and the physicochemical
properties of molecules as bit strings (Bajorath [2001b], Bajorath [2002]). Molec-
ular information encoded in fingerprints can be derived from arbitrary molecular
representations such as 3D conformational models, 2D graphs, or even 1D repre-
sentations like the molecular formula. Based on the way bit positions are associ-
ated with molecular features, one can further distinguish fingerprints into keyed
and hashed designs. In keyed fingerprints, each bit accounts for the presence or
absence of a given feature, such as a substructure, or, alternatively, whether or not
the value of a property descriptor lies within a certain range. Different concepts
have been suggested for the encoding of numerical descriptors into fingerprints
(Xue et al. [2003]; Eckert and Bajorath [2006a]). In Xue et al. [2003], the statis-
tical median of the screening database is used to transform the descriptor values
of compounds into a dichotomous variable. Thus, if the descriptor value of a
molecule is less than or equal to the database median, the corresponding bit is set
to 0 - and to 1 if it is greater. The concept of a keyed fingerprint (Barnard and
Downs [1997]) is illustrated in Figure 1.2. A popular 2D keyed fingerprint is the
MACCS keys fingerprint based on a subset of 166 MDL substructures.6
Other examples of keyed fingerprints include designs that are based on con-
nectivity patterns of atom types or pharmacophoric features. Via analysis of the
environment of heavy atoms, a fingerprint termed MOLPRINT 2D has been cre-
ated that consists of count vectors reporting the number of atom types at a given
distance from the reference atom (Bender et al. [2004a]). Furthermore, patterns of
3D pharmacophores (Figure 1.1) are usually recorded in 3D keyed fingerprints that
can contain several millions of bits based on systematic conformational enumer-
ation (Bradley et al. [2000]). On the other hand, 2D pharmacophore fingerprint
6MACCS structural keys. MDL Information Systems Inc., San Leandro, CA, USA.
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Figure 1.2: Example of a 2D keyed fingerprint. Given a set of 16 fragments, a
fingerprint containing the same number of bits can be generated for a given molecule.
The value of a bit is set to 1 if the fragment is present; otherwise, it is set to 0.
Color–coded fragments are taken from the subset of 166 publicly available MACCS
keys. Their arrangement in this example does not correspond to their position in the
MACCS fingerprint used in this thesis.
designs can be created by ignoring the 3D information and replacing the spatial
distances with bond distances. For instance, TGD, as implemented in MOE7,
is an example of a 2–point 2D pharmacophore fingerprint that generates phar-
macophore patterns from seven atoms types such as hydrogen bond donor and
acceptor, combined with their binned graph distances. Different from keyed fin-
gerprint designs, hashed fingerprints map feature patterns to bit sets that overlap
such that the presence of a certain feature is only given with some probability
(James and Weininger [2008]). Daylight fingerprints are an example of 2D hashed
fingerprint designs that capture connectivity pathways in molecules (James and
Weininger [2008]).
The basic principle of similarity analysis on the basis of molecular fingerprints
is to quantify the degree of overlap between the fingerprints of two molecules.
In the past, a large variety of similarity or distance metrics have been devised
(Holliday et al. [2002]) that use the information about identical and different bit
7Molecular Operating Environment. Chemical Computing Group, Montreal, Canada.
http://www.chemcomp.com
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settings to calculate a single value indicating the degree of similarity or dissimi-
larity between two molecules. In similarity searching, the screening database can
then be ranked in the order of decreasing similarity to the template molecule(s).
According to the similarity property principle, compounds with similar biological
activity are likely to be enriched among top–ranked compounds so that one can
select an arbitrary number of top–scoring compounds for activity evaluation.
Mapping algorithms for ligand–based virtual screening
An integral part of many chemoinformatics approaches, and in particular of most
molecular similarity–based methods, is the generation of chemical reference spaces
(Johnson and Maggiora [1990]; Stahura and Bajorath [2003, 2005]). Many meth-
ods in library design (Martin [2001]; Schnur et al. [2004]) and compound classi-
fication (Stahura and Bajorath [2003, 2005]) apply arrays of molecular property
descriptors (Todeschini et al. [2000]; Livingstone [2000]) to construct spaces of
chemical features that provide a basis for the analysis of molecular similarity
relationships or compound diversity. In context of virtual compound screening
(Stahura and Bajorath [2005]; Bajorath [2002]) and target–focused library design
(Schnur et al. [2004]), the relevance of the chosen chemical space representations
for the evaluation and prediction of biological activity is of paramount impor-
tance (Bajorath [2002]; Lipinski and Hopkins [2004]). This is because these meth-
ods cannot succeed if selected descriptors do not respond to activity–determining
molecular features.
A number of attempts have been made to rationalize feature selection for the
design of chemical reference spaces and to ensure their appropriateness for the
problems under investigation. For instance, by introducing the receptor–relevant
subspace concept, Pearlman and Smith [1999] attempted to study compounds in
chemical reference spaces formed by complex orthogonal descriptors that com-
bine chemical features generally known to be important for mediating specific
receptor–ligand interactions. This concept assumes that compounds, that prefer-
entially populate certain subspaces and cluster along selected descriptor axes, are
likely to share similar biological activity. Therefore, so–generated reference spaces
are generally relevant for the study of target–ligand interactions. Taking another
approach, Agrafiotis et al. [2002] generated low–dimensional reference spaces by
selection of those descriptors from high–dimensional space representations that
are responsible for the feature variance within a set of compounds. Also, parti-
tioning algorithms as described in Xue and Bajorath [2002] systematically search
for descriptor combinations that group classes of active compounds and make
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them distinguishable from others. Furthermore, descriptor assessment based on
information theoretic concepts has been successfully applied to guide for effective
descriptor selection (Godden and Bajorath [2002]).
Recently, methods termed mapping algorithms have been developed that fa-
cilitate the design of activity–class directed chemical reference spaces by select-
ing descriptor combinations that have systematically different settings in differ-
ent sets of compounds. Until now, four mapping algorithms have been intro-
duced including Dynamic Mapping of Consensus Positions (DMC, Godden et al.
[2004a]), Mapping to Activity–class specific Descriptor value ranges (MAD, Eck-
ert and Bajorath [2006b]), Dynamic MAD (DynaMAD, Eckert et al. [2006]), and
Continuous–Adaptive DynaMAD (CA–DynaMAD, Vogt and Bajorath [2008]).
Operating on binary transformed molecular descriptors (Xue et al. [2003]),
DMC generates consensus bit strings that reflect preferential bit settings among a
set of template compounds. These consensus bit strings are created in a stepwise
manner, and each subsequent consensus bit string allows for more bit variability.
During this process termed dimension extension, the number of consensus bit set-
tings increases. After each dimension extension step, the bit strings of compounds
from the screening database are mapped to the consensus bit string, that is, it is
examined whether or not the bit string of a database compound matches the con-
sensus bit string. If this is not the case, the compound is discarded; otherwise,
it is retained for the next dimension extension step. As shown by Godden et al.
[2004b], it is possible to direct this mapping process towards the identification of
more potent compounds.
Based on the foundations of descriptor–specificity assessment in MAD,
DynaMAD was developed for generating and navigating high–dimensional chem-
ical space representations and efficient processing of very large compound
databases. The method automatically selects descriptors from basis sets using
a descriptor scoring function that calculates the probability of a database com-
pound to map the descriptor value range of a set of reference molecules (typically
a set of active compounds). According to their score, descriptors are assigned to
dimension extension levels in order of decreasing reference–set specificity. Analo-
gous to DMC, the mapping process iteratively maps database compounds to the
value ranges of descriptors of the current dimension extension level and retains
only those compounds that match all value ranges.
Being the latest mapping algorithm, CA–DynaMAD constitutes an advance-
ment to DynaMAD in shifting the notion of reference–set specificity of descriptors.
After selection of the current top–scored descriptor and subsequent compound
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mapping, all other descriptors are re–evaluated on the basis of the remaining
database compounds. In DynaMAD, descriptor scores allow to draw conclusions
about activity–specificity for each descriptor individually and independent of other
descriptors. In CA–DynaMAD, however, scores for all but the first selected de-
scriptor are dependent on the set of previously chosen descriptors. Hence, refer-
ence space generation is focused on efficiently separating the database compounds
from the templates. The result is that chemical reference spaces created with
CA–DynaMAD tend to be of significantly lower dimensionality than those cre-
ated with DynaMAD. At the same time, they are at least equally if not more
activity–specific with respect to the compound database. Thus, the chance of
missing compounds in the database that are active but structurally distinct to
the template set is reduced.
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Thesis Outline
The investigations that are presented in this thesis attempt to answer a number
of questions that focus on the aspects of ligand potency and selectivity and on
the question to what extent 2D LBVS methods are suitable for their analysis:
Question 1 Are 2D virtual screening methods capable of discriminating between
active compounds with different potency for a given target?
Question 2 Given two sets of active compounds binding to two related targets
with differing target–selectivity, can conventional two–dimensional molecular
fingerprints enrich compounds with desired selectivity in reasonable sized
selection sets?
Question 3 Is it possible to distinguish sets of compounds that are selective for
one target from compounds that are active against the target family?
Question 4 Can one create target–selective chemical reference spaces suitable for
model building as well as for large–scale virtual screening?
For this purpose, a wide range of methods are examined that are based on differ-
ent molecular features of variable complexity derived from 1D and 2D molecular
representations. These methods are used to conduct virtual screening exper-
iments aiming at the detection of active compounds with desired potency or
target–selectivity using carefully assembled ligand databases and large compound
collections. The inclusion of biological screening data makes it possible to validate
the obtained results and evaluate their potential for practical applications.
Chapter 2 is concerned with the methodological aspects of this study. Ini-
tially, it is explained how ligand potency can be measured and how conclusions
about target–selectivity can be derived. Then descriptions of the methods under
investigation are provided, covering state–of–the–art as well as recently pub-
lished approaches for molecular similarity analysis. Finally, an improvement of
an existing dynamic mapping algorithm is introduced that is well–suited for the
generation of target–selective chemical reference spaces.
In Chapter 3, four consecutive studies are presented in detail that were con-
ducted in order to answer the aforementioned questions. By analyzing biological
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screening data it is shown that similarity search methods are able to distinguish
potent ligands from less potent ones. Based on these findings, the two following
studies document that compound mapping algorithms and 2D molecular finger-
prints of varying complexity show promising performance in selectivity search
calculations. The results of the final study substantiate the utility of chemi-
cal similarity–based approaches for analysis of ligand selectivity by generating
target–selective reference spaces.
Finally, Chapter 4 summarizes the results of these studies and presents con-
clusions.
Chapter 2
Methods
This chapter introduces the computational methods that are applied in the stud-
ies reported herein. Initially, it is explained how the potency of protein ligands
can be experimentally measured and how target–selectivity can be derived from
potency differences. The methodological spectrum of virtual screening methods
investigated in this thesis covers several 2D molecular fingerprint designs, dy-
namic mapping algorithms, and standard classification methods like clustering
and recursive partitioning.
2.1 Compound Potency and Target Selectivity
Often, high–throughput screening is applied to identify potential drug candidates
in early–stage drug discovery programs, particularly when little or no knowledge
about the structure of the target is available. In the context of drug discovery, an
assay is a test for modulatory activity with respect to a biological or biochemical
mechanism exerted by an active compound. In an automated fashion, HTS runs
a screen of an assay against a large compound library in a short time period.
Many therapeutic drugs are small molecule ligands that act as enzyme in-
hibitors. Upon binding, the enzyme’s ability to bind substrate1 is lowered and/or
its catalytic activity is decreased. Enzyme activators on the other hand, increase
an enzyme’s catalytic activity. In addition to enzymes, receptors are another
important class of therapeutic targets (Overington et al. [2006]). The activity
of receptors is regulated by binding interactions with agonists, inverse–agonists,
and antagonists. Binding of antagonists to the active or an allosteric binding
1A chemical entity that is altered by an enzyme
15
2.1. COMPOUND POTENCY AND TARGET SELECTIVITY 16
site prevents agonist–induced receptor response, while inverse–agonists cause the
opposite receptor response upon binding to the active site.
For testing compound activity with high–throughput screening, solutions with
a defined concentration of compounds2 are filled into the wells of microtiter plates.
Depending on the type of assay, cells or enzymes are added to each well and
after a predefined incubation time it is automatically measured if a desired effect
has occurred. Typically, each compound is tested at a single concentration in
the primary screen, so that the outcome is of a qualitative nature. That is, a
compound is either classified as being active or inactive, given their ability to
exert a minimum degree of target modulation. Active compounds yielded by the
primary screen, so called initial hits, are then subjected to a subsequent assay for
dose–response confirmation. By testing the initial hits several times at varying
concentrations it is possible to calculate a measure of compound potency.
The term potency is generally used to refer to a quantitative measurement
of a compound’s ability to interfere with the function of its target and is closely
associated with the terms IC50, EC50, and Ki. For competition binding and
functional antagonist assays IC50 is the most common measure of potency, EC50
for activator/agonist assays. In the following, IC50 and Ki will be explained with
respect to competitive enzyme inhibitors. However, these concepts analogously
apply to enzyme activators and receptor agonists.
If an enzyme inhibitor competes with the enzyme’s substrate to bind to its
active site, it is termed a competitive inhibitor, and its potency can be experi-
mentally measured in a competition or displacement assay. In this type of assay,
a fixed concentration of a labeled substrate is used as a reference to determine
the potency with which the unlabeled inhibitor competes for the binding. For
this purpose, the specific binding of the labeled ligand is monitored at different
concentrations of the unlabeled inhibitor. Afterwards, results are fitted to a logis-
tic function3, which is then used to determine the concentration of the unlabeled
inhibitor at which the binding of the labeled ligand is half maximal (see Figure
2.1) (Motulsky and Christopoulos [2003]). This concentration is called the IC50
of the unlabeled drug, and depends on its own affinity for the target and on the
binding affinity and concentration of the labeled ligand. The affinity of the un-
labeled ligand for the target is expressed as its equilibrium dissociation constant
Ki, which can be calculated with Equation 2.1 (Cheng and Prusoff [1973]).
2Pure or a mixture of several compounds
3A logistic function or logistic curve models the S–curve of growth of some set P.
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Figure 2.1: Competitive binding curve. The concentration of the unlabeled ligand
at which the labeled ligand binds to half of the available active sites is called IC50. NSB
stands for non–specific binding and refers, for example, to binding to cell membranes.
Ki =
IC50
1 + [labeled ligand]
Km
(2.1)
In Equation 2.1, Km is the Michaelis constant of the labeled ligand, its concentra-
tion at half maximal enzyme reaction rate in the absence of a competitive inhibitor
(approx. Kd under certain conditions). The Ki value is the concentration of the
unlabeled ligand at which it will bind to half of the binding sites at equilibrium,
in the absence of other competitors (Motulsky and Christopoulos [2003]). There-
fore, the lower the Ki value is for an competitive ligand, the higher its affinity is
for the target. Based on the nature of the IC50 value, it should not be mistaken
as a direct measure of affinity, but rather as a measure of a ligand’s ability to
interfere with labeled ligand/substrate binding to the active site (Motulsky and
Christopoulos [2003]). However, as applied concentrations of the labeled ligand
are usually at or closely below its Kd one can assume that IC50 values tend to
be a low multiple of the Ki values. In summary, Ki and IC50 values define a
compound’s ability to bind to its target in different contexts but are nevertheless
interrelated as shown by Cheng and Prusoff [1973] and can thus both be regarded
as comparable quantifications of compound potency.
If one needs to measure the selectivity of an active compound for a given
target with respect to other targets, it is necessary to obtain information about
its potency for each of the targets first. Then, the pairwise selectivity selABi of a
compound i for targetA over targetB can be calculated according to Equation 2.2.
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selABi =
PotBi
PotAi
(2.2)
PotAi and Pot
B
i are either the Ki or IC50 values of compound i for targets A and
B. When selABi > 1, the compound shows selectivity for target A over target
B. Usually, in order to allow a meaningful analysis of compound selectivity,
one might want to apply threshold values for this measure of target–selectivity.
Therefore, selectivity thresholds of 50– or 100–fold were applied in all reported
target–selectivity related studies herein. Throughout this thesis, a set of active
compounds, which are selective for target A over target B, is denoted by A/B.
2.2 2D Fingerprints
One of the most popular class of tools for similarity searching are molecular fin-
gerprints, which encode information about molecular properties and structure in
sets of features, mainly as ordered bit strings. Although such sets or strings are
themselves 1D, they are able to capture chemical features from various higher di-
mensional molecular representations (2D graph, 3D surfaces, 3D pharmacophores)
and thus enable computationally efficient similarity analysis in large compound
databases. Its advantage over compound classification methods is that the knowl-
edge of only one known bioactive compound is sufficient. This compounds serves
as search template, while classification methods such as machine learning or Bayes
classification depend on the availability of multiple template structures (Bajorath
[2002]). Nevertheless, many studies have shown that fingerprint performance in
similarity search calculations further increases in the majority of cases when using
multiple reference compounds (Hert et al. [2006]).
For similarity searching with molecular fingerprints one also needs to quantify
the overlap of two fingerprints. A variety of such functions called similarity metrics
exist (Holliday et al. [2002]), of which three of the most widely used ones are listed
in Table 2.1. These metrics try to relate the number of commonly set bits (that is,
set to 1) to the number of set bits in each of the bit strings and return similarity
values between 0 and 1, where 1 denotes a perfect match. It should be noted that
binary fingerprints bear no information about how often a feature is present in a
molecule. If a bit is set to 1 it only means that the corresponding feature is found
at least once. A understanding of this is crucial for the correct interpretation of
results of similarity analysis based on fingerprints. For instance, if the Tanimoto
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Metric Range Formula
Cosine [0, 1] c√
a+b
Dice [0, 1] 2·c
a+b
Tanimoto [0, 1] c
a+b−c
Table 2.1: Similarity metrics for dichotomous variables. Three examples of common
functions (also called coefficients) used to measure fingerprint similarity. The Tanimoto co-
efficient is also known as Jaccard coefficient. Given two fingerprint bit strings A and B, a
and b are the number of bits set to 1 in the corresponding strings and c is the number of bits
set to 1 in both strings. There also exist formulations for continuous variables (Willett et al.
[1998]).
coefficient (Tc) calculated from the MACCS fingerprints of two compounds is 1,
the only valid conclusion is that the bit strings are identical, but not necessarily the
molecules themselves. To overcome this potential problem, molecular holograms
have also been introduced that record the number of feature occurrences in an
integer string (Flower [1998]).
When searching with only one template structure, all compounds from the
screening database are compared to it and ranked in decreasing order of similar-
ity values. If multiple templates are available there are several different search
strategies, including the centroid (Schuffenhauer et al. [2003]) and nearest neigh-
bor approaches (Schuffenhauer et al. [2003], Hert et al. [2004]). The centroid ap-
proach involves the generation of an averaged fingerprint (see Figure 2.2b) whose
similarity to database compound fingerprints has to be measured by utilizing a
metric suited for continuous variables, for example, the formulation of the Tc for
continuous variables (Willett et al. [1998]). This technique, as well as related ap-
proaches such as fingerprint scaling (Xue et al. [2001]), emphasizes features that
are specific for a set of active compounds and thus potentially correlated with
biological activity. As a data fusion technique, the nearest neighbor approach
merges pairwise similarity values between a database compound and the k most
similar reference compounds by averaging. The examples shown in Figures 2.2c
and 2.2d visualize nearest neighbor strategies with k = 1 and k = 5 (1NN and
5NN, respectively).
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(a) Single template (b) Centroid
(c) 1NN (d) 5NN
Figure 2.2: Similarity search strategies. Red dots represent database compounds
and black dots and circles represent template compounds that are included in the
calculation of the similarity value or not. The blue dot indicates the centroid position
calculated from all template fingerprints.
2.2.1 MACCS
Probably one of the best known and widely used structural 2D fingerprints is based
on a subset of MDL MACCS structural keys4. It monitors the presence of 166
small topological structural fragments none of which considers information about
stereochemistry (McGregor and Pallai [1997]). Figure 2.3 shows a compound
containing substructural features that are detected by six MACCS keys. See
Appendix Table A.2 for a complete listing of the 166 structural keys used to
generate the MACCS fingerprint.
4Symyx Software, San Ramon, CA, USA.
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(a)
Key Description
65 N in aromatic bonds with C
77 N separated by 2 bonds
83 heteroatoms in 5 ring
89 O separated by 4 bonds
99 C in C=C
162 aromatics
(b)
Figure 2.3: MACCS substructural keys. In (a) a caffeine molecule is shown with
six highlighted substructural features that correspond to the MACCS keys listed in
(b). The binary MACCS fingerprint detects the absence or presence of those features
in a compound, indicated by bit settings of 0 or 1, respectively.
2.2.2 MOLPRINT 2D
Calculated from the 2D connectivity table, MOLPRINT 2D (Bender et al.
[2004a,b]) represents molecules by a set of atom environments, each of which
reports the occurrence of SYBYL atom types (Clark et al. [1989]) up to a given
distance from the center atom. In this thesis, atom environments up to a distance
of two bonds are considered for the generation of the atom environments, as rec-
ommended by Bender et al. [2004a]. Figure 2.4 illustrates the concept of atom
environments as implemented in the MOLPRINT 2D fingerprint. The fingerprint
itself is not a bit string but consists of a set of strings generated from the count
vectors, as shown in Figure 2.4b. The size of the set is correlated to the num-
ber of heavy atoms in a compound, and up to 250 unique atom environments are
theoretically possible (from the combinatorial point of view).
2.2.3 TGT
The Typed Graph Triangle fingerprint implemented in MOE calculates 3–point
pharmacophore features from a 2D graph representation of a molecule. All atoms
are classified according to a set of four atom types: hydrogen bond donor or
base, hydrogen bond acceptor or acid, both hydrogen bond donor and acceptor,
and hydrophobic. From this set of typed atoms all possible atom triplets are
generated and the graph distances (that is, the number of bonds in the shortest
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(a)
Layer Atom types
0 C.ar
1 C.ar, N.2, N.am
2 C.2, N.pl3, C.2, C.3, C.2
(b)
Figure 2.4: Illustration of atom environments as used in MOLPRINT 2D.
(a) For each heavy atom, all atoms, classified according to SYBYL atom types, are
reported up to a distance of two bonds. The count vectors listed in (b) are combined
into a single atom feature, and the set of all such features present in a compound
constitutes its corresponding MOLPRINT 2D fingerprint.
(a)
Typed graph triangles
(Don, Don, Don, 4, 4, 4)
(Don, Don, Hyd, 4, 3, 3)
(Don, Don, Hyd, 4, 5-9, 3)
(b)
Figure 2.5: Example of three different typed graph triangles. In (a), four atoms
are highlighted according to their atom type in blue (hydrogen bond donor, Don) and
green (hydrophobic, Hyd). Combined with their bond distance intervals, these four
atom types can used to generate three unique, symmetry–free TGT features as shown
in (b).
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path connecting two atoms) between all pairs are determined and binned into six
distance categories {1, 2, 3, 4, 5-9, 10-}. This information is then coded as feature
tuples and their presence is then recorded in the fingerprint. In total, the TGT
fingerprint accounts for 1 704 unique 3–point pharmacophore features.
2.2.4 MP–MFP
As a hybrid design, the MP–MFP fingerprint (Xue et al. [2003]) originally com-
bines 110 selected MACCS keys and 61 binary transformed molecular property
descriptors, where the selection of descriptors and structural features was deter-
mined by the analysis of their information content in a large compound database.
For molecular descriptors, their information content was measured on the basis of
Shannon entropy analysis (Godden et al. [2000], Godden and Bajorath [2002]) in
a large compound database, and those with high Shannon entropy and thus high
information content were subsequently subjected to correlation analysis. Elimi-
nation of highly correlated descriptors with less information content resulted in
a set of 61 molecular descriptors (Xue et al. [2003]). More than half of these
descriptors carry implicit 3D information by approximating molecular surface
areas from 2D representations onto which various physicochemical properties are
mapped (Labute [2000]). Based on the median partitioning approach of Godden
et al. [2003], selected descriptors were binary encoded based on the statistical
medians in the screening database. Thus, if a compound’s descriptor value is
above the database median, the corresponding bit is set to 1, or 0 if it is not.
In addition, 110 MACCS keys were chosen that displayed relative bit frequencies
between 10% and 90%, omitting those substructural keys having low discrimina-
tory power. The current design is summarized in Table 2.2, which was obtained
by adapting the MACCS keys selection to the statistics of the ZINC6 database.
As both bit settings (0 and 1) of the binary encoded property descriptors have an
equivalent information content, a new similarity coefficient was defined based on
the Tc for dichotomous variables (see Table 2.3). As formulated in Equation 2.3,
avTc =
Tc1 + Tc0
2
(2.3)
the so called average Tc (avTc) is defined as average of the two Tanimoto coef-
ficients Tc1 and Tc0, measuring the ratio of coincident 1s and 0s, respectively.
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Descriptor class # Descriptors
Complex surface area descriptors 31
Atom and bond counts 16
van der Waals surface descriptors 6
Topological descriptors 4
Partial charge descriptors 3
Physicochemical descriptors 1
(a)
MACCS keys
19, 32, 33, 36, 38, 42, 50-55, 57-62, 64-67, 69,
71-100, 102-149, 151-162, 164
(b)
Table 2.2: Constitution of the MP–MFP fingerprint. For the presented studies the MP–
MFP design was adapted to the ZINC6 database, combining (a) 61 2D molecular property
descriptors with (b) 113 MACCS keys into a fingerprint consisting of 174 bits. See Appendix
Chapter A for details on the used molecular descriptors and MACCS keys.
2.2.5 PDR–FP
The ultimate goal in ligand–based virtual screening is the identification of com-
pounds with diverse structures and similar activity to template compounds, often
referred to as lead hopping. As a consequence, virtual screening methods ap-
plied for lead hopping should not be entirely based on molecular representations
that over–emphasize structural similarity such as structural keys. The design of
the recently developed PDR–FP fingerprint (Eckert and Bajorath [2006a]) follows
this idea and is based on extensive and careful analysis of 2D molecular property
descriptors and their relevance for bio–activity.
For this purpose, the DynaMAD scoring function (see Equation 2.16) was used
to assess general activity class–specificity of 184 1D and 2D property descriptors
implemented in MOE. This analysis resulted in the selection of a set of 93 descrip-
tors (Eckert and Bajorath [2006a]). The generation of PDR–FP depends on the
screening database statistics of these 93 descriptors. The descriptor value ranges
are divided into non–overlapping intervals so that the same number of database
compounds fall into each of them. Descriptor value ranges can be binary encoded
by associating each interval with a single bit, which results in a fingerprint size of
500 bits in accordance with the binning scheme applied by Eckert and Bajorath
[2006a]. Then, bit strings are generated by mapping the calculated descriptor
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values to the descriptor intervals. Bits associated with intervals into which a com-
pounds descriptor values fall are set to 1, all other bits are set to 0. Hence, there
are always exactly 93 bits set to 1, which makes PDR–FP size–independent. For
the analysis of compound similarity in the presence of multiple reference com-
pounds, an activity–oriented search string is created in a second step that reflects
the descriptor value distributions of the template set relative to the distribution
of the screening database. As the binning of descriptor value ranges into inter-
vals directly depends on the value distributions of the screening database, the
concentration of template compounds in only a very small number of intervals
indicates activity–specificity. By summing up all bit frequencies from the search
string that correspond to bits set on in the fingerprint of a database compound
and normalizing by the sum of maximum bit frequencies for all descriptors, com-
pound similarity between the screening database and multiple reference structures
is expressed by the similarity coefficient given in Equation 2.4.
SV =
∑500
i=1 xiyi
NF
(2.4)
In this equation, NF is the normalization factor. The maximum value of 1 is
achieved if all set bits in a fingerprint coincide with all bits that have the highest
frequency among all template compounds. If the descriptor values of the database
compound do not match any interval whose search string value is above zero, the
compound is assigned the lowest PDR coefficient of 0.
2.3 Mapping Algorithms
The mapping algorithms described in the following sections are distinct from con-
ventional ligand–based virtual screening methods and are especially designed for
multiple template screens. Common to these approaches is the determination of
activity–specific consensus positions in chemical space, whether represented as
fingerprints or unmodified descriptor values. A consensus position is defined as a
set of features that fulfill pre–selected activity–specific requirements. Compounds
from the screening database are mapped to a consensus position and the result
serves as basis for similarity analysis. In DMC and DynaMAD, this procedure is
iteratively applied by assigning features to different layers that correspond to con-
sensus positions of varying specificity. Distantly related to other approaches such
as cell–based partitioning, mapping algorithms do not require the computation of
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pairwise distances between the multiple reference compounds and the screening
database. Thus, computational costs are generally lower than for similarity search
methods.
DMC, MAD, and DynaMAD create chemical reference spaces from indepen-
dent descriptor contributions. By contrast, CA–DynaMAD refines the initial con-
sensus position in a stepwise manner by adding only descriptors that maximize
the separation from the reference database.
2.3.1 DMC
DMC (Dynamic M apping of Consensus positions) is a mapping algorithm that
seeks to identify consensus positions of active compounds in simplified descriptor
spaces of stepwise increasing dimensionality. These chemical reference spaces are
generated from 1D and 2D molecular descriptors that have been simplified in
advance by binary transformation. Initially, the statistical medians of descriptor
value distributions in the screening database are determined. Then, the position
of each active compound in the chemical space created by all descriptors is binary
transformed. If the descriptor value of a compound is larger than the database
median, the corresponding bit is set to 1; if the compound’s descriptor value is
less than or equal to the median, it is set to 0. Once all active compounds are
assigned a descriptor bit string, the descriptor scoring function given in Equation
2.5 is applied using the mean bj of the bit settings to indicate bit variability at
position j inside the activity class.
scoreDMC = |0.5− bj | (2.5)
If all bit settings are identical, the descriptor values of the template compounds
fall on the same side of the database median and top scores of 0.5 are achieved.
This indicates a potentially class–specific feature. On the other hand, descriptors
are assigned the minimal score of 0 if they show maximal variability, that is, half of
the descriptor values of the templates are less than or equal to the median, and the
other half is above. Based on the descriptor scores, consensus positions permitting
stepwise increasing variability can be determined. The initial consensus position,
permitting no variability, is defined by a descriptor vector composed of descrip-
tors with a score of 0.5. By allowing increasing bit setting variability, consensus
positions are generated that no longer require identical descriptor settings for all
active compounds. According to their amount of tolerated variability, consensus
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positions are assigned to different layers. Layer 0 defines the initial consensus
position and starts with the descriptors having a score of 0.5. Subsequently, the
permitted variability is increased by a certain value, which is determined using
Equation 2.6.
StepwidthDMC =
1
#actives
(2.6)
For example, if the activity class consists of 10 compounds, all descriptors with
a score of 0.4 are assigned to layer 1, those with a score of 0.3 to layer 2, and
so on. Only descriptors with a score of 0 are not assigned to any layers, because
they show no class–specificity. Thus, DMC implements dimension extension by
allowing class–size dependent bit setting variability per extension step. Figure
2.6 illustrates the generation of consensus positions in DMC and compares it to
POT–DMC.
Finally, starting with the initial consensus position, the mapping process be-
gins. During mapping it is examined if the bit string of a database compound
coincides with all bit settings of the current consensus position. If it does, the
compound is retained for the next mapping step. Because consensus positions
that allow increasing bit variability include more descriptors, proceeding to the
next step and mapping the remaining compounds to the next consensus position is
termed dimension extension. The dimension extension process is continued until
a specified number of database compounds remain.
2.3.2 POT–DMC
In order to emphasize the contribution of highly potent active compounds over less
potent ones, a scaling function was devised and incorporated into DMC. Prior to
descriptor scoring, the potency–scaled DMC algorithm (POT–DMC, Godden et al.
[2004b]) calculates for every active template compound i the logarithmic scaling
factor SF according to Equation 2.7, based on the comparison of its potency, poti,
to the lowest one, potmin.
SFi = log10(potmin)− log10(poti) + 1 (2.7)
As the potencies of active compounds can span several orders of magnitude, the
use of logarithmic scaling functions avoids dominance of the most potent templates
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by linear scaling. The lowest scaling factor possible is 1. Thus, this scaling
function ensures that even less potent compounds are considered and the general
structural information is taken into account. The scaling factors are applied when
bit frequencies are determined, namely by summing and normalizing scaled bit
values according to Equation 2.8.
b′j =
∑n
i=1 SFi × bij∑n
i=1 SFi
(2.8)
SFi and bij are the scaling factor and the value of bit j of active compound
i, respectively. Subsequently, these potency–scaled bit frequencies are used to
calculate consensus position as described. As shown, potency scaling effectively
means that during calculation of bit frequencies compounds are counted multiple
times based on their scaling factor, the definition of the stepwidth in POT–DMC
has to be adapted, as shown in Equation 2.9.
StepwidthPOT-DMC =
1∑n
i=1 SFi
(2.9)
Whereas the initial consensus position at layer 0 remains unaffected compared to
DMC, the consensus positions of successive dimension extension are influenced by
the weighted compound contributions.
Figure 2.6 shows the key concepts of DMC and POT–DMC and elucidates the
differences. This example shows four template compounds C1 −C4 with different
potency, which are represented by fingerprints consisting of eight binary encoded
descriptors. Based on the potencies given as IC50 values, the scaling factors can be
computed with the help of the logarithmic scaling function given in Equation 2.7;
their range lies between 1 for compound C3 with the lowest potency and 3.6 for
compound C2, which is 400–fold more potent. In the lower left corner, the result-
ing scores for each method are reported. When comparing DMC and POT–DMC
scores of each bit position the effect of scaling becomes apparent. POT–DMC
scores for bit positions two, four, and seven are significantly higher than DMC,
while the score for bit position six is lower. These differences in scoring directly
translate to the generation of consensus positions. For POT–DMC, bit position
six is set to zero only in the last dimension extension (POT–DMC consensus po-
sition CP4), while bits two and four are already set in consensus positions one
to three, resulting in differences in the composition of chemical reference space.
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Figure 2.6: Comparison of DMC and POT–DMC. In the top left corner four
examples of compound bit strings of length eight are shown. Bit frequency analysis
reveals three high–, three medium–, and two non–specific bit settings, as is reflected by
the DMC scores reported in red. Therefore, DMC generates two consensus positions
as illustrated in the lower right corner. The use of the scaling function in POT–DMC
increases the contributions of potent compounds and results in different descriptor
scores (reported in green). Consequently, consensus positions of DMC and POT–
DMC can differ.
Remarkably, bit seven, which is one of two descriptors that seemingly do not dis-
play activity–specificity, is assigned a significantly higher score by POT–DMC (as
opposed to being assigned a score of 0 by DMC), because its value is identical for
both highly potent compounds C1 and C2. Thus, the corresponding descriptor
setting contributes to CP4 of POT–DMC, while it remains variable in all DMC
consensus positions.
For all DMC and POT–DMC calculations reported herein, 155 1D and 2D
molecular property descriptors implemented in MOE were used and binary trans-
formed with respect to the screening database, as described above.
2.3. MAPPING ALGORITHMS 30
2.3.3 MAD
Figure 2.7: Overlap profiles for MAD descriptor scoring. This example shows
the value distribution of a descriptor in a large compound database and how the value
ranges of four different active classes, represented by the colored bars at the bottom,
overlap with the three subranges of the database. The value ranges indicated by black
and orange bars are examples for partial and complete overlap with the central range
of the database, thus showing less activity specificity. The value ranges indicated by
green and blue bars show higher specificity due to small range sizes and location in
the upper or lower database subrange, where a maximum of 25% of the database can
match these ranges.
Further pursuing the concept of generation of activity–specific chemical refer-
ence spaces, the MAD algorithm (M apping of Activity–specific Descriptor value
ranges, Eckert and Bajorath [2006b]) focuses on the comparison of descriptor value
distributions of activity classes and screening databases. Descriptors are scored
depending on the degree of overlap of their activity class value ranges with the
value distribution of the database used for screening.
In MAD, descriptor value distributions inside the screening database are
represented by their 25%– and 75%–quantiles, q0.25 and q0.75, which devide the
database value range into three subranges, whereas for activity classes the entire
value ranges are used as defined by the minimum and maximum values, classMin
and classMax. The implemented scoring scheme distinguishes between three
overlapping profiles defined by Equation 2.10 and illustrated in Figure 2.7.
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scoreMAD =


q75−q25
sizeRange
if classMin ≥ q25 OR classMax ≤ q75
2 · q
25−dbMin
sizeRange
if classMax < q25
2 · dbMax−q
75
sizeRange
if classMin > q75
(2.10)
In case of sizeRange = 0, all active compounds have the same descriptor value,
and while this is a likely sign of activity specificity, the corrections in Equations
2.11 - 2.14 apply.
δddb =
σddb
200
(2.11)
classMinnew = classMinold − δ
d
db (2.12)
classMaxnew = classMaxold + δ
d
db (2.13)
sizeRangenew = 2 · δ
d
db =
σddb
100
(2.14)
In Equations 2.11 to 2.14, σddb is the standard deviation of the descriptor inside
the database. A score that is greater than 1 generally indicates that less than
half of the database compounds fall within the value range of the active class.
In particular, when the value range has no overlap with the central range, the
score is greater than 2 and at most 25% of the database match (Eckert and
Bajorath [2006b]). Hence it is possible to select descriptors that show activity
class specificity to generate a tailored chemical reference space. Experiments in
Eckert and Bajorath [2006b] have shown that a score threshold of 1 is already
sufficient to produce meaningful results. On the basis of selected descriptors, the
simple similarity measure shown in Equation 2.15 captures how good a compound
matches all value ranges, where D is the total number of selected descriptors
and M the number of descriptors whose value ranges are matched by the given
compound.
sMAD =
M
D
(2.15)
Thus, MAD similarity scores can adopt values between 0 and 1; larger values
suggest higher similarity to the active compounds.
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2.3.4 DynaMAD
As a further refinement of the concepts developed in DMC and MAD, DynaMAD
(Eckert et al. [2006]) combines scoring of descriptor value ranges with dynamic
extension of chemical reference spaces. Instead of using the value range size and
the overlapping profile to estimate how activity–specific a given descriptor is, it
directly measures the probability with which database compounds map to its
value range. Similar to DMC, descriptor scores are then used to build chemical
reference spaces of stepwise increasing dimensionality, until a desired termination
criterion is met.
The underlying notion of descriptor specificity is that the fewer database com-
pounds are likely to map the value range spanned by the minimum and maximum
value (classMin and classMax) of the activity class, the more specific this value
range is. Therefore, the descriptor scoring function of DynaMAD was designed to
capture mapping probabilities of database compounds as shown in Equation 2.16.
scoreDynaMAD = (1− P (classMin ≤ X ≤ classMax)) · 100 (2.16)
The mapping probability of discrete descriptor values is defined according to Equa-
tion 2.17.
P (classMin ≤ X ≤ classMax) =
∑
classMin≤xi≤classMax
P (X = xi) (2.17)
Continuous descriptor values are combined into mini ranges [xi1, xi2] and the
calculation of mapping probabilities follows Equation 2.18 (Eckert et al. [2006]).
P (classMin ≤ X ≤ classMax) =
∑
classMin≤xi2;classMax≤xi1
P (X ∈ [xi1, xi2])
(2.18)
Scores obtained by application of Equation 2.16 range between 0 and 100 and give
the percentage of database compounds that do not map the respective descrip-
tor value range. Hence, high scores correspond to high descriptor specificity as
illustrated in Figure 2.8.
Then, similar to DMC, descriptors are assigned to different mapping layers
based on their degree of activity–class–specificity. Therefore, the entire scoring
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(a) scoreDynaMAD = 96.0 (b) scoreDynaMAD = 77.9
(c) scoreDynaMAD = 50.8 (d) scoreDynaMAD = 26.1
Figure 2.8: Descriptor specificity and DynaMAD scores. Shown are four different
value distributions of molecular descriptors of ∼3.7 million ZINC7 compounds and,
indicated by red bars, the value ranges of a set of 37 dopamine D3 selective antagonists
(Stumpfe et al. [2007]). From (a) to (d) descriptor specificity decreases as mirrored
by the DynaMAD scores.
range is divided into equally sized intervals, and all descriptors whose score fall
into the same scoring interval define one layer. In the original implementation,
20 scoring intervals of size five were chosen, designating the top–scoring range as
layer 0, and representing descriptors with scores ≥ 95. As layer 0 contains the
most specific descriptors, it is the most appropriate layer to start the mapping
process with. Database compounds are mapped to all value ranges of descriptors
contained in this layer, and qualify for the next mapping step upon successful
matching to all of these ranges. Thus, dynamic dimension extension in DynaMAD
is achieved through the consecutive addition of descriptor layers to which database
compounds are mapped. This process is continued until a predefined termination
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criterion is met, for example, a specified number of compounds remain.
In summary, DynaMAD is able to generate and efficiently navigate high–
dimensional chemical space representations due to its automated descriptor se-
lection scheme. This scheme is based on the evaluation of independent descrip-
tor value range specificity for a given class of active compounds and a screening
database.
2.4 Design of CA–DynaMAD
Given the ability of DynaMAD to generate compound class–directed chemical
space representations, the question arises whether it might be possible to sys-
tematically design target–selective chemical spaces. In the context of similarity
searching, assessing compound selectivity is more complicated than searching for
active compounds because it is required to distinguish chemically related com-
pounds from each other that have differential activities against multiple mem-
bers of a target family. Consequently, chemical reference spaces for such tasks
must be designed in previously unexplored ways. However, for applications in
chemical biology and medicinal chemistry, computational methods that are ca-
pable of analyzing and predicting ligand selectivity profiles within target families
are highly attractive (Bajorath [2008]). By developing new schemes for scoring
and dimension extension, a second generation DynaMAD–like mapping algorithm
was created termed Continuous–Adaptive DynaMAD (CA–DynaMAD, Vogt et al.
[2008]), that allows for better control of dimension extension and explicitly con-
siders coherences among descriptors. To achieve this, the algorithm evaluates one
descriptor per step and performs descriptor value range analysis on the basis of
the continuously updated (size–reduced) background compound database.
Continuous Dimension Extension
In order to overcome stringency–related problems and ineffective descriptor se-
lection as occasionally observed in DynaMAD, the dimension extension process
is refined in CA–DynaMAD. Instead of assigning multiple descriptors to a single
dimension extension step, descriptors are added one–by–one in order of decreas-
ing scores, thereby continuously increasing dimensionality of the reference space.
In case multiple descriptors have the same score, the descriptor with the lowest
correlation to all previously selected descriptors is chosen. The correlation of de-
scriptor i with n previously chosen ones is calculated as an average of the sum
of absolute values of Pearson’s product–momentum correlation coefficients r as
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stated by Equation 2.19.
corri =
1
n
n∑
j=1
|rij | (2.19)
In Equation 2.19, pairwise descriptor correlation rij can be computed from the
screening database or from another adequate set of compounds. For the current
implementation of CA–DynaMAD the MDDR, version 2005.2, was analyzed.
Adaptive Descriptor Scoring
Descriptor scoring as introduced in DynaMAD requires the comparison of activ-
ity class value ranges and database distributions of these descriptors. In the case
of DynaMAD, the descriptor distributions are calculated only once for the ini-
tial screening database, which typically contains a large number of compounds
(∼ 3.7 million in the case of used ZINC7 version, see Appendix Chapter B.2 for
further details). These distributions are then used to calculate fixed descriptor
scores according to Equation 2.16. During the ensuing mapping process, the num-
ber of compounds is continuously reduced, thereby changing the descriptor value
distributions, in particular during the first dimension extension steps when large
numbers of compounds are discarded. Thus, descriptors proposed by DynaMAD
might not be an optimal choice at any dimension extension level, except the first.
Therefore, CA–DynaMAD utilizes an adaptive scoring scheme that repeats the
descriptor scoring process after each dimension extension step with recalculated
mapping probabilities for the size–reduced database, subsequently updating de-
scriptor scores.
The example calculations presented in Table 2.3 illustrate the effects of adap-
tive descriptor scoring used in CA–DynaMAD compared to the fixed scoring
scheme of DynaMAD. As a test system, 37 selective D3 antagonists were used as
templates and 10 000 ZINC7 compounds were randomly selected as a screening
database. Then, five mapping steps were carried out, with fixed descriptor scoring
like in DynaMAD or with adaptive scoring. As can be seen in Table 2.3, the first
mapping step is identical for both scoring schemes. When comparing the remain-
ing mapping steps, the differences become apparent. First of all, the mapping
method based on adaptive scoring retains approximately ten times fewer decoys
from the screening database after five dimension extensions. In addition, com-
parison of the selected descriptors reveals that the generated reference spaces are
2.5. REFERENCE METHODS 36
Step Descriptor scorefixed scoreadapt ZINC710k
1 GCUT SLOGP 0 77.9 77.9 2 207
2 BCUT SLOGP 0 76.5 6.4 2 065
3 GCUT SMR 0 72.3 22.1 1 608
4 PEOE VSA FPNEG 70.4 49.4 813
5 BCUT SMR 0 68.1 44.4 452
(a) Fixed scoring
Step Descriptor scoreadapt scorefixed ZINC710k
1 GCUT SLOGP 0 77.9 77.9 2 207
2 PEOE VSA+0 60.1 58.0 881
3 GCUT SLOGP 3 72.4 64.5 243
4 BCUT PEOE 3 59.3 66.6 99
5 PEOE VSA FPNEG 54.5 70.4 45
(b) Adaptive scoring
Table 2.3: Fixed versus adaptive descriptor scoring. Given a set of 37 D3 antagonists
and a random sample of 10 000 compounds from ZINC7, five mapping steps are reported for
fixed and adaptive descriptor scoring, adding the best–scoring descriptor per step. scorefixed
and scoreadapt report the calculated fixed scores and the adapted scores, respectively. For
comparison, scores according to both scoring schemes are reported for each descriptor.
significantly distinct from each other, only sharing two descriptors. Furthermore,
analysis of the scores reveal that the descriptors with high constant scores lose
specificity when mapping progresses and are less effective in deselecting decoys
than descriptors chosen on the basis of adaptive scores.
2.5 Reference Methods
This section briefly presents methods that are used for reference calculations
throughout the studies reported herein, including standard classification meth-
ods like clustering and partitioning as well as a method especially designed for
molecular similarity analysis.
2.5.1 Cluster Analysis
In general, the classification of a set of objects into different subsets according
to a measure of similarity is termed clustering. Cluster analysis is a widely used
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Figure 2.9: Hierarchical clustering. Divisive hierarchical clustering methods start
from a single cluster, the root of the dendrogram, which is successively divided into
smaller clusters. Agglomerative methods start with each object in a separate cluster,
also called a singleton, and then successively merge clusters until all objects are placed
into a single cluster.
technique and applied in a variety of different fields such as data mining, pattern
recognition, bio– and chemoinformatics. Methods for data clustering can be di-
vided into two main groups based on their general approach of cluster–generation.
Hierarchical clustering algorithms generate a succession of clusters, where newly
built clusters are derived from their predecessors and the established hierarchy
can be represented using a dendrogram. As is shown in Figure 2.9, there exist
two different types of hierarchical clustering approaches: divisive and agglomer-
ative. Divisive hierarchical clustering starts with all objects in one cluster and
then divides the clusters in a stepwise manner such that the distance between the
newly created clusters is maximized, proceeding until all objects are partitioned
into clusters of size 1. By contrast, agglomerative hierarchical clustering starts
with all objects in separate clusters, subsequently combining at each step the pair
of clusters with the shortest distance, until all objects are placed into a single
cluster. Linkage methods describe how the distance dAB between clusters a and
b is determined. Three examples of common linkage methods are presented in
Table 2.4. An alternative approach of hierarchical cluster analysis was proposed
by Ward (Ward [1963]) which is not based on a distance measure between, but
on statistical variance within the clusters.
Contrary to this, non–hierarchical or partitional clustering algorithms estab-
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Single Linkage dAB = mini,j d(xi, yj) shortest distance be-
tween members of
clusters A and B, where
xi ∈ A and yi ∈ B
Complete Linkage dAB = maxi,j d(xi, yj) greatest distance be-
tween members of
clusters A and B
Average Linkage dAB =
1
k·l
∑k
i=1
∑l
j=1 d(xi, yj) average distance between
all members of clusters A
and B
Table 2.4: Linkage methods for clustering. Shown are three common methods to deter-
mine the degree of association between clusters.
lish a partitioning of the objects without hierarchical relationships among the
clusters, and there exist several approaches on how clusters can be generated. As
an example, k–means clustering is a relocation method that initially generates a
pre–defined number of clusters and then iteratively re–assigns objects to these
clusters in order to improve the quality of the clustering. Another approach of
non–hierarchical clustering is based on the analysis of nearest neighbors, for which
the algorithm introduced by Jarvis–Patrick is a widely known example.
The following two subsections introduce the methods by Ward and Jarvis–
Patrick as examples of hierarchical and non–hierarchical clustering algorithms.
Ward’s Clustering
Ward’s clustering (Ward [1963]) is an agglomerative clustering algorithm that
seeks to minimize the loss of information resulting from joining two clusters, where
information loss is defined as an error–sum–of–squares criterion (ESS). At each
step of the clustering procedure, all possible cluster unions are evaluated and those
with minimum information loss are finally applied.
With a simple example of univariate data, Figure 2.10 explains the concept
of Ward’s clustering. Given a set of values (2, 6, 5, 6, 2, 2, 0, 0, 0, 2) associated
with ten objects, combining all ten objects in one cluster would result in an ESS
of 50.5 (Figure 2.10a). On the other hand, clustering the objects according to
their values into four clusters as depicted in Figure 2.10b would result in an ESS
of 0. In other words, Ward’s method forms clusters so that the cluster variance is
minimized.
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(a)
(b)
Figure 2.10: Ward’s clustering. (a) Sub–optimal clustering. (b) Optimal cluster-
ing. The overall error–sum–of–squares is the sum of error–sum–of–squares of each
individual cluster.
Jarvis–Patrick Clustering
Jarvis–Patrick clustering (Jarvis and Patrick [1973]) is a non–hierarchical clus-
tering method that is based on the nearest–neighbor principle. Apart from a
suitable distance measure, it requires two parameters J and K. For each object,
the J nearest neighbors are determined. Two objects will then be placed into the
same cluster if they appear in each other’s nearest–neighbor lists and have at least
K other nearest neighbors in common. Figure 2.11 illustrates the concept of the
Jarvis–Patrick clustering with an example of 12 objects that are partitioned into
two clusters. It should be noted that by following this algorithm not all objects
in the same cluster necessarily have at least K neighbors in common. If there are
three objects l, m and n, and l and m have K neighbors in common like m and
n, all three objects are placed into the same cluster even though l and n might
have less than K common neighbors.
The Jarvis–Patrick clustering calculations are reported in Chapter 3.3 and use the
MACCS fingerprint as molecular representation and the pairwise Tc similarity as
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Figure 2.11: Jarvis–Patrick clustering. Based on the values of the input parame-
ters, J = 5 and K = 3, two clusters are formed. Optimization of clustering results
can be achieved by systematically varying J and K.
a measure of association.
2.5.2 Recursive Partitioning
The recursive partitioning (RP) technique belongs to the group of tree–based
methods for statistical data analysis whose primary goal is to act as an expert
system for classifications (Friedman [1977]; Rusinko et al. [1999]). However, it has
also been used to identify important variables associated with object properties
of interest (Zhang et al. [2001]). Although a number of different RP implemen-
tations exist, they share the basic concept of how a decision tree is created for
classification.
Figure 2.12 explains the recursive partitioning process. Suppose there is a train-
ing set t1 consisting of 38 observations of which 22 belong to class A and 16 to
class B. These observations are represented by two properties x and y. Based on a
measure of purity, a split of the training set according to any of the two properties
is sought that results in an increase of purity in the terminal nodes, called leaves.
The simplest purity measure is the absolute purity of terminal nodes with respect
to classes A and B. Determination of class labels for the leaves as shown here is
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(a)
(b)
Figure 2.12: Recursive partitioning. Two classes of observations, A and B, are
recursively split into subsets based on the two properties x and y. Each split leads
to an overall increased purity of decision tree leaves, which correspond to the newly
generated subsets.
a majority voting method where the most prominent class in a leaf determines
the class assignment. As shown in Figure 2.12a, the best split initially is achieved
when asking the question:
Is x less or equal to 0.7?
In a recursive manner, each of the two newly created subsets t2 and t3 is subse-
quently analyzed to determine, if further splits are possible that improve terminal
node purity. In this case, only splitting subset t2 at y = 0.55 is feasible, which
leads to the generation of the subsets t4 and t5 with a purity of 83 and 81.8%,
respectively. Essentially, this procedure can be carried out until each leaf contains
only one observation, but in this case the decision tree would be overfitted and
less suited for class prediction. Thus, a stopping criterion for the recursive process
needs to be chosen, for example, a maximum number of observations in leaves or
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a purity threshold. In case of the example of Figure 2.12, a minimum leaf purity
of 80% was applied.
2.5.3 DACCS
The DACCS method (D istance in Activity–C entered Chemical Space, Godden
and Bajorath [2006]) is designed to operate in high–dimensional but unmodified
descriptor spaces and takes contributions of many arbitrarily chosen descriptors
into account. As illustrated in Figure 2.13, DACCS centers chemical reference
space through a scaling procedure on a subspace populated by a set of reference
molecules. It then approximates this subspace as an orthogonal system by calcu-
lation of Euclidian–like distances from the center of the subspace to all compounds
in a database. Thus, DACCS calculations generate a distance–based ranking of
database compounds from the centroid of an active subspace. Given a set of
known active reference compounds, the distance in scaled chemical space from
the center of the “active subspace” is calculated for database compounds as in
Equation 2.20.
dDACCS =
√√√√ d∑
i
(
xi − µi
σi
)2
(2.20)
In Equation 2.20, xi is the value of one of the d descriptors for a compound x,
µi the mean value of descriptor i for a set of active template compounds, and
σi is the standard deviation of the descriptor values for the templates. If this
standard deviation is zero, then the standard deviation of the entire compound
population is used instead. If both values are zero, the descriptor is omitted from
the calculation (which would apply to a descriptor having the same value for all
active and database compounds).
In POT–DACCS, the logarithmic potency scaling function initially devised
for POT–DMC (see Equation 2.7) becomes effective when the means and stan-
dard deviations are calculated for centering the active subspace. Under scaling
conditions, descriptor values of potent compounds have a greater effect on the
means and standard deviations than weakly potent compounds. Thus, the de-
scriptor statistics change through the weight put on the values of more potent
compounds. Essentially, this causes these values to be counted several times more
than the ones of weakly potent molecules. As a consequence, the active subspace
is shifted towards the positions of potent compounds.
CHAPTER 2. METHODS 43
Figure 2.13: The DACCS algorithm. Black dots represent a subset of reference
molecules used to calculate the centroid of an active subspace (dotted circle) and open
dots database compounds located close to or within the subspace. Arrows indicate
Euclidian–like distances of compounds from the centroid.
Chapter 3
Structure–Selectivity
Relationships
In this chapter, four studies are presented that investigate the suitability of 2D
ligand–based virtual screening methods to analyze structure–selectivity relation-
ships. In particular, multiple 2D molecular fingerprints and a new class of 2D
LBVS methods termed mapping algorithms are applied to study their ability to
distinguish between active compounds with differential target selectivity profiles.
Initially, it is shown that similarity search and classification methods are able
to capture potency–relevant molecular features and can be directed to preferen-
tially detect potent compounds based on the analysis of biological screening data.
Then, extensive benchmark calculations with five different fingerprint designs, two
mappings algorithms, and several reference methods are conducted, aiming at the
identification of compounds with desired selectivity. Again, biological screening
data are included in order to validate the results under more realistic VS con-
ditions. The final study establishes that the most advanced mapping algorithm
can be used to generate chemical reference spaces useful for the generation of
predictive models for target selectivity.
3.1 Analysis of HTS Data
In this section, the analysis of biological screening data obtained from a cathepsin
B HTS experiment is presented. This analysis was conducted with the aid of two
conceptionally distinct approaches, which can be extended to incorporate potency
information of template compounds by inclusion of a scaling function. The results
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suggest that LBVS methods are suitable for potency–directed compound analysis
drawing upon knowledge gained from HTS data.
Experimental Setup
The HTS data set was generated at the Penn Center for Molecular Discovery at
the University of Pennsylvania1 using an assay for inhibitors of cathepsin B, a
cysteine protease in lysosomes, and made public through PubChem. It consists
of 63 332 compounds including 40 hits with IC50 values ranging from 46 nM to
46 µM. Examples of hits are shown in Figure 3.1. The structural resemblance of
active compounds was evaluated on the basis of average pairwise Tanimoto coef-
ficients calculated for MACCS fingerprints. The similarity of active and inactive
molecules was assessed using single template search calculations with MACCS
keys fingerprint for each known active against the remainder of the database.
For VS trials, 30 sets of ten active compounds each were randomly selected
as reference compounds while the remaining 30 active compounds were added to
the set of inactives. The only preselection requirement was that the reference
compounds had to cover the experimentally observed potency range in order to
ensure realistic potency scaling. Each set of reference compounds was individually
used as input for scaled and nonscaled DACCS and DMC calculations. For search
calculations, a set of 155 1D and 2D molecular descriptors was calculated with
MOE. For DMC and POT–DMC calculations, descriptor medians were calculated
for the HTS data set.
Characterization of HTS Data
Initially, the distribution of hits in the HTS set and the similarity of active and in-
active compounds was analyzed. Three compounds were active below 100 nM and
five additional ones below 1 µM; 17 hits had potency in the range between 1 and
10 µM, and the remaining 15 hits were active above 10 µM concentration. Thus,
the potency distribution of active molecules was continuous but relatively narrow,
with most compounds being active in the low micromolar range. The mean and
median potencies were 13.2 µM and 6.9 µM, respectively. Highly potent (that
is, low nanomolar) compounds are rarely found in primary screening data sets.
However, despite moderate average potency, the cathepsin B set contained a total
of eight sub–micromolar hits including three highly active compounds. Figure 3.2
1The Penn Center for Molecular Discovery (PCMD).
http://www.seas.upenn.edu/~pcmd
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Figure 3.1: Representative cathepsin B HTS hits. Most of the cathepsin B
inhibitors have a unique core structure and are of limited structural complexity.
reports the results of pairwise MACCS Tc comparisons of potent compounds. In
the Tc matrix, off–diagonal red patterns indicate significant similarity between
hits. The figure reveals that similarity between hits was limited to relatively few
(of 780 possible) compound pairs. Many comparisons yielded Tc values of 0.5 or
less, which indicates dissimilar compounds in terms of MACCS structural keys.
Similarity was greatest among seven potent (top–left red cluster) and seven weakly
active (lower right) compounds. The two most active compounds were similar to
each other, but also to a significantly less potent molecule, and compounds in the
second top–left cluster were also found to display distinct similarity to five weakly
active ones in total. Therefore, compound potency within this set did not clearly
correlate with compound similarity, as can be observed from the representative
structures shown in Figure 3.1. Active compounds were not confined to one or two
analog series, which would have also been reflected in a higher intraset similarity.
Table 3.1 reports the results of MACCS similarity search calculations within
the screening set using each hit individually as a query. A considerable number of
inactive data set compounds were found to be structurally similar or very similar
to hits, including nearly identical compounds. At a MACCS Tc level of 0.90 or
greater, nearly 200 matches of hits to inactive compounds were detected. At a
MACCS Tc threshold value of ∼0.85, the structural resemblance of compounds
was clearly visible, and nearly 700 matches were detected at this level. These
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≤ 1µM ≤ 10µM > 10µM
Figure 3.2: Similarity analysis of HTS hits. Structural analysis of cathepsin B HTS
hits using a matrix of pairwise MACCS Tc similarity values, ordered by increasing IC50
values. Tc values are reported in matrix–format for systematic pairwise compound
comparisons. The values are color–coded according to following scheme: dark green
0-0.2, light green 0.2-0.4, yellow 0.4-0.6, orange 0.6-0.8, red 0.8-1. Among all potency
subranges as indicated, significant compound diversity can be observed, while at the
same time a subset of similar compounds spans the entire potency range.
findings nicely illustrate that Tc values alone are not a reliable indicator of similar
activity (Martin et al. [2002]), and that very similar structures can either be active
or inactive (Kubinyi [1998]). The latter point is well–known in medicinal chemistry
and analog design and presents an intrinsic limitation of methods that evaluate
similarity from a whole–molecule perspective (Bajorath [2002]; Bender and Glen
[2004]). In conclusion, significant structural diversity among hits is observed on
one hand, while on the other hand these active compounds are structurally similar
to a considerable number of inactive compounds.
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IC50 [nM] 1.00 (1.00, 0.95] (0.95, 0.90] (0.90, 0.85] (0.85, 0.80]
46.1 0 0 0 1 7
71.0 0 0 0 0 11
72.2 0 0 0 1 14
246.6 0 5 5 14 43
434.6 0 2 7 8 16
691.9 0 5 8 19 105
844.5 0 0 0 0 3
923.5 0 5 7 16 92
1 185.1 1 3 22 47 64
1 260.8 0 2 6 8 14
1 639.5 0 0 0 0 0
1 749.1 0 5 7 12 75
1 990.0 0 6 4 17 71
2 087.4 1 0 5 0 1
2 120.0 0 0 0 0 0
2 247.2 1 0 6 53 217
3 170.9 0 0 6 16 62
4 169.7 0 0 0 1 1
6 355.6 0 0 1 3 8
6 714.5 0 1 10 16 29
7 113.8 0 0 0 2 16
8 563.1 0 0 3 19 102
8 926.9 0 0 1 17 38
9 388.7 0 0 0 1 13
9 562.6 2 5 10 37 132
11 457.8 0 0 0 1 4
12 265.1 2 6 12 56 144
12 947.1 0 0 1 1 0
14 196.4 0 0 0 3 23
18 349.1 0 1 3 12 34
19 686.4 0 0 0 2 3
28 132.2 0 0 2 5 48
33 855.4 2 1 1 1 5
37 190.0 0 0 0 2 20
38 470.6 1 0 0 1 4
39 986.8 0 0 1 1 19
44 181.1 0 0 1 2 27
44 577.0 0 1 3 56 237
44 782.6 0 0 0 3 29
46 161.2 0 0 3 44 160
Sum 10 48 135 498 1 891
Table 3.1: Single template search calculations with MACCS fingerprint. Reported are
the number of inactive compounds within a Tc similarity range between 0.8 and 1. Hits are
sorted by decreasing potency (IC50).
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DMC and DACCS Calculations
In order to determine whether active molecules could be retrieved from the HTS
set irrespective of their potency levels, individual nonscaled search calculations
using different sets of reference compounds were analyzed. Results obtained for
DMC and DACCS are reported in Tables 3.2 and 3.3, respectively. For DMC,
active compounds were found at the final dimension extension levels. In a few
cases, the selection sets contained a large number of inactive compounds together
with two or three hits, for example, in trials 13 and 21 in Table 3.2. For prac-
tical VS applications, such calculations would not be suitable because too many
database compounds would need to be evaluated. However, most calculations
produced reasonably sized selection sets, and in nine trials, one or two inhibitors
were recovered together with only approximately ten or even fewer inactive com-
pounds. The majority of DACCS calculations reported in Table 3.3 also detected
inhibitors. Five trials failed to produce active molecules among the top-scoring
100 compounds, but 14 calculations revealed between one and six hits among
the top 50 compounds with, on average, 3.5 inhibitors per trial. The remaining
calculations produced between one and six active molecules among the top 100
compounds. In general, the results of DMC and DACCS calculations were much
influenced by the composition of the reference molecule sets, which has also been
observed in VS benchmark calculations (Bajorath [2002]).It has to be considered
that, different from benchmarking, hit and recovery rates are not a primary mea-
sure of success for VS applications because compound recall cannot be determined
in practical screens. Furthermore, the ability to identify novel active molecules
in small VS selection sets is much more relevant than actual hit rates, which rep-
resent a more suitable measure for large–scale screening campaigns. Since both
DMC and DACCS calculations consistently retrieved active molecules from the
HTS data sets, it was possible to explore the key question of whether or not in-
creasingly potent inhibitors would be detected under the conditions of potency
scaling.
Comparison of DMC and POT–DMC
The comparison of DMC and POT–DMC search calculations revealed that both
methods detected an overall comparable number of hits as reported in Table 3.2.
However, POT–DMC recognized fewer inactive molecules in 17 of 30 calculations,
which considerably reduced the size of the selection sets. In a number of cases, the
reduction in the number of inactive molecules was quite dramatic, for example,
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Trial DMC POT–DMC
1 5/435 1/221
2 2/196 3/39
2/12
3 2/4 3/24
1/2 2/9
4 1/41 1/34
5 2/97 2/36
1/15 1/3
6 2/24 4/9
2/4
7 1/11 1/2
8 2/663 2/92
1/19
9 1/13 2/36
1/4
10 8/749 2/285
11 1/223 1/160
12 2/269 1/70
13 2/5 320 2/1 669
14 1/93 1/7
15 1/23 2/29
1/4 1/4
16 1/466 1/9
Trial DMC POT–DMC
17 3/189 3/82
2/4 2/9
18 2/98 2/493
19 1/7 2/37
1/2
20 1/49 2/14
21 3/780 2/152
22 2/64 3/8
23 1/62 1/3
24 3/36 2/4
2/4 2/2
25 1/170 2/5
26 1/20 3/55
1/2
27 2/80 2/60
1/4
28 1/61 2/36
1/8 1/2
29 1/60 3/23
1/12
30 2/49 4/47
2/12
Table 3.2: Hits in DMC and POT–DMC compound selection sets. Results of 30 individ-
ual search calculations with DMC and POT–DMC are summarized. For each calculation, hits
identified at the final or second to last dimension extension level are reported. For example,
“2/24”means that the compound selection set contained two cathepsin B inhibitors and 22
inactive compounds.
in trials 8, 21, or 25. Thus, potency scaling increased the specificity of the calcu-
lations. Next, the potency distribution of the identified inhibitors was analyzed.
POT–DMC detected on average 1.3 hits with potency <1 µM in selection sets of
fewer than 100 compounds, whereas DMC detected on average 0.6 of these hits.
The POT–DMC retrieval rate was considerable because only four potential hits
with <1 µM potency were available in the screening set. POT–DMC also detected
approximately twice as many hits as DMC with a potency of up to 10 µM but
did not detect hits with >10 µM potency. Thus, there was a consistent trend
of POT–DMC calculations to enrich selection sets with more potent compounds
than DMC.
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DACCS POT–DACCS
Trial S50 S100 S50 S100
1 0 1 3 4
2 0 0 0 0
3 4 5 5 5
4 0 0 2 3
5 5 6 5 5
6 1 1 1 4
7 0 0 0 0
8 6 6 5 5
9 0 0 1 1
10 2 4 3 4
11 4 4 6 6
12 0 1 0 0
13 5 6 6 6
14 0 2 1 1
15 0 0 1 2
DACCS POT–DACCS
Trial S50 S100 S50 S100
16 0 0 1 1
17 2 3 3 3
18 3 4 4 5
19 4 5 5 5
20 1 1 0 0
21 0 1 1 2
22 0 1 1 1
23 6 6 5 5
24 0 0 1 1
25 0 0 0 0
26 1 1 3 3
27 5 5 5 5
28 0 2 1 2
29 0 1 0 0
30 0 0 0 0
Table 3.3: Hits in DACCS and POT–DACCS compound selection sets. For individual
DACCS and POT–DACCS calculations, the number of hits contained in selection sets of 50
(S50) or 100 (S100) database compounds are reported.
Underlying effects could be studied by analyzing the mapping pathways of
hits with different potencies to consensus bit strings during dimension extension,
as reported in Figure 3.3. For DMC, there were only little differences in the
mapping characteristics of active compounds, although some potent compounds
reached higher dimension extension levels than the weakly potent molecules. By
contrast, for POT–DMC, significant changes were observed. Here, weak hits were
eliminated earlier during the search than in DMC calculations, but the most potent
hits were found in much higher dimension levels than in nonscaled calculations,
which resulted in a distinct separation of more and less potent compounds during
POT–DMC calculations. In both cases, search strings consisting of a small number
of consensus bits produced comparable results. The reason for this is that at the
beginning of the calculations, only low bit variability is permitted, which results in
a suppression of the scaling effect. The observation that potent hits were retained
under increasingly stringent search conditions during POT–DMC calculations can
be explained when considering the fact that POT–DMC generates consensus bit
settings that selectively favor highly potent molecules.
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Figure 3.3: Potency distribution of hits at increasing dimension extension
levels. Shown is a comparison of compounds matching search strings of increasing
length in DMC and POT–DMC calculations. Consensus positions reports the number
of accepted descriptor bits. During dimension extension, the number of descriptor
consensus bits increases. Black circles represent database compounds, green circles
hits with >10 µM potency, and red circles hits with <1 µM potency.
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DACCS versus POT–DACCS
Next, the effects of POT–DACCS were investigated. This method is algorith-
mically distinct from POT–DMC since it produces a distance–based ranking of
database compounds. As shown in Table 3.3, POT–DACCS calculations identi-
fied more hits than DACCS in approximately half of the trials. In all of the trials
that produced hits, POT–DACCS achieved higher average potency for retrieved
compounds than DACCS. For example, among the top scoring 100 data set com-
pounds, POT–DACCS recognized on average one of the four most potent hits
available in the database, whereas DACCS recognized on average only ∼0.3. Sim-
ilar to POT–DMC, POT–DACCS displayed a tendency to deselect weakly active
hits relative to DACCS and generally did not rank them among the top scoring
100 compounds.
In contrast to POT–DMC, compound ranking also needs to be taken into
account when evaluating POT–DACCS. On the basis of systematic rank versus
potency comparisons, two effects were found to be responsible for the enrichment.
POT–DACCS ranked potent hits more highly than DACCS and assigned lower
ranks to weakly potent hits, which resulted in an enrichment of most potent hits
at higher rank positions, as shown in Table 3.4. Overall, the average rank position
of the most potent hits within the top scoring 100 compounds was 25 for DACCS
and 19 for POT–DACCS, and for hits with potency between 1 µM and 10 µM,
the average rank was 23 for DACCS and 20 for POT–DACCS. For hits with
potency >10 µM, an average rank of 34 was determined for DACCS, whereas
POT–DACCS did not select weakly potent hits among the top 100 compounds.
These findings confirmed that POT–DACCS assigned lower ranks to weakly active
hits than DACCS and higher ranks to increasingly potent hits. Given the findings
discussed above, it was attempted to illustrate the effects of potency scaling in
an intuitive manner. Since DACCS operates in unmodified descriptor spaces, a
Potency [µM] DACCS POT–DACCS
< 1 25.4 19.4
1− 10 23.2 19.8
> 10 33.7 –
Table 3.4: Comparison of DACCS and POT–DACCS. Reported are the average ranks of
active compounds among the top 100 compounds.
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Figure 3.4: Compound distributions and centroids. A sample of the cathepsin
B HTS data set was projected into a three–dimensional descriptor space. Hits with
potency <1 µM are represented as green dots, hits with potency >10 µM as blue
dots, and inactive compounds as small gray dots. Average centroid positions for all
DACCS (black cross) and POT–DACCS calculations (red) are mapped.
systematic search was carried out for combinations of three property descriptors
that would produce a notable separation of more and less potent hits in a three–
dimensional representation. An example is shown in Figure 3.4. Here, mapping
a random sample of 5 000 inactive compounds from the HTS data set into a
space constituted by three intuitive descriptors (logP(o/w), molecular weight,
and approximated van der Waals volume) produced a visible separation of more
and less potent inhibitors. Of course, this descriptor combination would not be
sufficient for VS because it did not separate active from inactive compounds.
However, despite its limited resolution, this reference space made it possible to
visualize the effects of potency scaling on the location of the centroid position.
Figure 3.4 reveals that potency scaling shifted the DACCS centroid position away
from weakly potent hits into a region predominantly occupied by molecules having
higher potency, which rationalizes why POT–DACCS calculations detected more
potent inhibitors. Therefore, at least in part the effects of potency scaling can be
attributed to re–centering of the activity–dependent subspaces. It is reasonable to
assume that similar changes in centroid positions also occur in high–dimensional
space representations when potency scaling is applied.
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3.2 Similarity Searching for Selective Ligands
After demonstrating that 2D VS methods are sensitive to molecular features that
relate to compound potency, the next step was to investigate whether such meth-
ods could also be used to distinguish between active compounds with different
target selectivity. Given an especially designed database of compounds with se-
lective activity against members of different protein families, similarity search
calculations were conducted with five different 2D molecular fingerprints. The
analysis of the results presented in this section shows that 2D molecular finger-
prints are suited to differentiate between compounds with different target selec-
tivity. Moreover, the fingerprints exhibited comparable performance, irrespective
of fingerprint design and complexity.
Experimental Setup
The molecular selectivity benchmark system (Stumpfe et al. [2007]) consists of a
total of 558 compounds selective against 13 individual targets belonging to three
different families: biogenic amine G protein–coupled receptors (GPCRs), papain–
like thiol proteases, and chymotrypsin–like serine proteases. The compounds are
divided into 26 selectivity sets containing varying numbers of compounds, as sum-
marized in Table 3.5. Compounds in each of the selectivity sets are selective for
one target over another closely related one. Therefore, each set represents an
individual test case. Importantly, the selectivity sets were assembled to cover dif-
ferent scaffold–selectivity relationships: they contain compounds having similar
scaffolds but different selectivity and also compounds having diverse scaffolds yet
similar selectivity. Compounds within a selectivity set often originate from differ-
ent sources or independent investigations, which further contributes to intra–set
diversity of compounds and scaffolds, as can be observed from the MACCS Tc
similarity matrices shown in Appendix Figures B.1, B.5 and B.6. Further details
are given in Appendix B.
Dependent on the sources of selective compounds, selectivity sets were added
to one of two different background databases for similarity searching. Compound
data for the cathepsins B, L, and S (in part) were taken from high–throughput
screening experiments and, therefore, a background database of confirmed inac-
tive compounds was assembled from high–throughput screens for inhibitors of
cathepsin B, L, and S, respectively. It consists of 55 055 compounds showing
no measurable activity against any of these targets (see Appendix Chapter B.2).
Ligands of GPCRs and inhibitors of serine proteases were generally taken from
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Target family Target Selectivity set Compounds
GPCRs D1 D1/D2 31
D1/D4 13
D2 D2/D1 26
D2/D4 9
D2/5HT1a 11
D3 D3/D4 12
D4 D4/D1 20
D4/D2 64
D4/D3 33
5HT1a 5HT1a/D2 24
5HT1a/Alpha1 46
Alpha1 Alpha1/5HT1a 27
Papain–like Cat B Cat B/Cat L 23
proteases Cat B/Cat S 23
Cat L Cat L/Cat B 33
Cat L/Cat S 33
Cat S Cat S/Cat B 23
Cat S/Cat L 23
Cat S/Cat K 20
Cat K Cat K/Cat S 25
Chymotrypsin–like Thrombin Thrombin/Trypsin 35
proteases Thrombin/Factor Xa 52
Trypsin Trypsin/Thrombin 20
Trypsin/Factor Xa 25
Factor Xa Factor Xa/Thrombin 49
Factor Xa/Trypsin 48
Table 3.5: Benchmark system for pairwise selectivity. Compounds in each set are selective
for one target over another family member. For example, the designation D1/D2 means that
the compounds in this set are selective for dopaminergic receptor subtype D1 over D2.
the scientific literature. These compounds were added to a subset of the ZINC6
database (Irwin and Shoichet [2005]), consisting of ∼1.44 million compounds con-
sidered as decoys. Five 2D fingerprints were chosen for this study that represent
different designs and, in addition, have significantly different complexity. Table
3.6 gives a short overview of selected fingerprints that are described in greater
detail in Chapter 2.
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Fingerprint Design
MACCS 166 structural fragment keys
MOLPRINT 2D atom environments, no bit representation
MP–MFP 174 bits, hybrid of selected binary transformed prop-
erty descriptors and MACCS keys
PDR–FP 500 bits, 93 value–range encoded property descriptors
TGT 1 704 unique 3–point 2D pharmacophore features
Table 3.6: Selected 2D molecular fingerprints.
Test Calculations
To evaluate different fingerprint designs for their ability to detect selective com-
pounds, multiple reference compounds were used and a nearest neighbor approach
for similarity scoring was applied (as described in Chapter 2.2). This type of sim-
ilarity search protocol has been shown to frequently perform best in comparisons
with alternative search strategies (Hert et al. [2004]; Willett [2006]). For each
selectivity set and fingerprint, 25 independent search trials were carried out with
randomly selected sets of reference molecules and the results were averaged. For
selectivity sets containing more than 15 compounds, ten reference molecules were
chosen. In the remaining sets, half of the compounds in each set were used as refer-
ence molecules and the other compounds were added to the background database
as potential hits. For reference sets of ten molecules, five nearest neighbors (5NN)
were considered when determining the similarity score for each database com-
pound; for reference sets of fewer than ten molecules, three nearest neighbors
(3NN) were chosen. For MACCS, TGT, MOLPRINT 2D, and MP–MFP, the
Tanimoto coefficient was chosen as similarity measure. For PDR–FP, similarity
is expressed by means of a specifically developed dot product metric (see Chapter
2.2.5).
Pairs of selectivity sets provided the basis for analyzing the potential of sim-
ilarity searching to detect selective compounds. For each target pair (A and
B), a two–step analysis was carried out. First, subsets of compounds selective
for A over B (set A/B) were taken as reference molecules and searched against
a background database containing the remaining selective A/B compounds and
also compounds belonging to set B/A. Then, the calculations were repeated us-
ing subsets of B/A compounds as reference molecules after adding the remaining
B/A and all A/B compounds to the database. This procedure made it possible
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to evaluate the search results at different ’selectivity levels’: (i) ’target–selective’
molecules had to belong to the same selectivity set as the reference molecules, that
is, compounds selective for the second target are considered false–positives; and
(ii) ’pair–active’ compounds belong to both selectivity sets (B/A and A/B). Thus,
for each target in a pair of targets, pair–active compounds are defined as the sum
of target–selective and false–positive compounds. Although the identification of
target–selective molecules is the ultimate goal of selectivity searching, the ability
to detect pair–active compounds also provides valuable information. This is the
case because pair–active compounds are active at the level of target families. A
search calculation should also identify compounds that are active at the level of
target families and distinguish them from irrelevant database compounds. Thus,
the identification of target–selective molecules and the ratio of target–selective
over pair–active compounds represent meaningful measures for the evaluation of
search calculations.
Selectivity Search Data
As outlined above, systematic search calculations were carried out for all 26 se-
lectivity sets and five fingerprints. In the following, representative results are dis-
cussed in Figures 3.5 and 3.6 that reflect major trends revealed in this analysis.
All remaining results are provided in Appendix Figures C.1 and C.2. Furthermore,
Appendix Table C.1 reports hit and recovery rates for all fingerprints and selectiv-
ity sets and selection sets consisting of the top–scoring 100 database compounds.
For each calculation, maximally possible hit rates are reported in Appendix Table
C.1. Maximum hit rates are calculated by dividing the number of selective com-
pounds that are available in the database as potential hits by the selection set
size. As stated above, for selectivity sets containing more than 15 compounds,
ten reference molecules were used and the remaining compounds were added as
potential hits to the database. For example, the D1/D2 set contains 31 com-
pounds and, in this case, the maximum hit rate for target–selective compounds is
21% (see Appendix Table C.1). The D2/D1 set contains 26 compounds and the
corresponding maximum hit rate is 16%. Accordingly, for the target pair (D1 and
D2), the maximum possible hit rate for pair–active compounds is 47%. Over all
selectivity sets, theoretically possible hit rates for target–selective molecules range
from 4% to 59%. These limits are important to consider when putting the search
performance into perspective. Table 3.7 reports average search results for each
fingerprint and the three target families studied here.
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Figure 3.5: Retrieval of selective compounds. In (a)-(c), the average recovery of
hits in selection sets of increasing size, ranging from 5 to 100 database compounds, is
reported. The leftmost data points correspond to the smallest selection set size of five
compounds; then, set sizes increase in increments of five compounds. The graphical
representations monitor the retrieval of target–selective versus pair–active compounds,
as defined in the text. The total number of recovered pair–active compounds is
reported (top horizontal axis) and also the rate (bottom). The vertical axis reports
the ratio of target–selective over pair–active compounds.
Detection of Target–Selective Compounds
Figure 3.5 monitors the recovery of target–selective versus pair–active compounds
in database selection sets of increasing size and Figure 3.6 reports average numbers
of correctly identified target–selective and pair–active compounds. Regardless of
the targets, a few general trends are clearly evident. All fingerprints are capable
of detecting target–selective compounds and in a number of cases (for example,
Figure 3.5a and Appendix Figure C.1d) their performance is almost indistinguish-
able. For other selectivity sets (for example, Figure 3.5b, 3.5c, and Appendix
Figure C.1i), in part significant differences in search performance are observed.
In a number of cases, selection sets of increasing size only enrich target–selective
but not false–positive active compounds (for example, Figure 3.5a and Appendix
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Figure 3.5: Continued.
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Figure C.1k), which is reflected by the fact that the ratio of target–selective com-
pounds remains at the 100% level. In other cases, false–positive active compounds
are gradually enriched as selection sets increase in size (for example, Figure 3.5c
and Appendix Figure C.1h). Thus, the curves in Figure 3.5 point downwards.
However, when there is a notable tendency to enrich false–positive active com-
pounds in selection sets, target–selective compounds are already enriched in small
selection sets. These findings suggest that limiting selection set size is likely to di-
rect search calculations towards exclusive detection of selective compounds. Thus,
if maximizing compound recall is not a primary objective, focusing on only small
numbers of top–scoring database compounds is a preferred search strategy for the
identification of target–selective compounds. This is relevant for practical appli-
cations, since the novelty or individual quality of chosen compounds is often a
primary objective, rather than the total number of active or selective compounds
one might be able to find.
Target– versus Pair–Active Compounds
Figure 3.6 compares the ratio of target–selective versus pair–active compounds for
different fingerprints and reveals that in most cases, significantly more selective
than false–positive active compounds are found, which is an encouraging result.
Furthermore, differences between fingerprints are only small for the majority of
selectivity sets. However, there are exceptions across all three target families. For
example, for the D2/D4 set (Figure 3.6a), TGT displays a significant tendency to
detect false–positive actives, in contrast to MACCS. However, both fingerprints
show comparable performance on target–selective compounds. For sets Cat K/Cat
S and Cat S/Cat K (Figure 3.6b and Appendix Figure C.2h), essentially all finger-
prints show a notable tendency to detect false–positive actives. In contrast, for
the trypsin/thrombin set (Figure 3.6c and Appendix Figure C.2i), only PDR–FP
has a high false–positive rate. Thus, fingerprints show differences in the ratio of
pair–active versus target–selective compounds on a case–by–case basis, but over-
all differences are surprisingly small and target–selective molecules are much more
frequently detected than false–positive active compounds.
Differences between Target Families
As shown in Appendix B.1, selectivity sets for all three target families differ in
their degree of intra–set structural diversity, although the GPCR ligands tend to
be on average more similar to each other than the protease inhibitors (Stumpfe
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Figure 3.6: Ratio of false–positive active versus target–selective compounds.
The bar graphs shown in (a)-(c) report the relative amounts of false–positive active
(light gray) and target–selective (dark gray) compounds for each fingerprint method
as an average number of these compounds in differently sized selection sets ranging
from 50 to 550 compounds. According to the definition in the text, the sum of
false–positive active and target–selective molecules are pair–active compounds. Total
numbers of pair–active compounds are reported in parentheses.
et al. [2007]). As expected, cathepsin inhibitors obtained from high–throughput
screening data sets were structurally most diverse. At least two structural factors
are expected to complicate selectivity analysis: (i) if compounds belonging to dif-
ferent selectivity sets have distinct structural similarity (as is the case for some
of the GPCR sets), it might be difficult to distinguish between them; (ii) if selec-
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Figure 3.6: Continued.
tive compounds show significant intra–set structural diversity (as is the case for
some of the cathepsin inhibitors), it might be difficult to recognize them as being
similar. However, the results in Figure 3.5 demonstrate that selectivity search
calculations are not systematically affected by general differences in intra–set and
inter–set structural resemblance. For example, calculations on a number of GPCR
sets and also on the Cat B/Cat S and Cat S/Cat B sets (Figure C.2f and C.2g) ex-
clusively produce selective compounds. On the other hand, the trypsin/thrombin
set generally produces more false–positives than the thrombin/trypsin set (Figure
3.6c and C.2i). Thus, the results of selectivity searching using fingerprints do
not simply correlate with differences in the structural resemblance of compounds;
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Figure 3.6: Continued.
compound class–selective features are indicated to play an important role.
Fingerprint Search Performance
Table 3.7 summarizes the average search performance of the different fingerprints
for the three target families. For selection sets of 100 database compounds, hit
rates for target–selective compounds are generally below 10% for GPCR ligands
and cathepsin inhibitors and above 10% for serine protease inhibitors. However, it
must be taken into account that theoretically possible hit rates for target–selective
molecules range from only 4% to 59% (see Appendix Table C.1), with an average
maximum hit rate of approximately 20% over all selectivity sets. Furthermore,
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Biogenic amine Papain–like Chymotrypsin–
GPCRs proteases like proteases
PAC TSC PAC TSC PAC TSC
MACCS
HR 9.4 8.2 4.8 4.6 11.6 10.5
RR 19.6 55.6 12.4 35.1 16.3 39.1
TGT
HR 7.6 7.1 6.2 5.1 11.6 11.0
RR 17.6 49.2 16.1 38.6 16.7 40.4
MOLPRINT 2D
HR 11.4 10.6 7.0 6.4 15.5 14.4
RR 26.4 69.4 18.3 46.7 22.4 52.0
PDR–FP
HR 6.3 5.9 6.0 4.5 19.2 12.4
RR 15.2 44.5 15.8 34.0 29.2 47.5
MP–MFP
HR 9.7 9.1 6.0 5.1 11.5 10.7
RR 22.7 61.2 15.6 38.4 15.8 38.9
Table 3.7: Average fingerprint performance. Comparison of family–based averaged sim-
ilarity search performance of the studied five fingerprints, evaluated according to hit and
recovery rates of pair–active (PAC ) and target–selective (TSC ) compounds, given as percent-
age.
comparable numbers of target–selective compounds are often found in selection
sets of much smaller size (Figure 3.5). As illustrated in Figure 3.6, only small
numbers of false–positive active compounds are detected in most cases. In addi-
tion, Table 3.7 shows that recovery rates for selection sets of the top 100 scored
compounds are significant, ranging from approximately 30% to 70% for target–
selective molecules. The fingerprints were chosen because they represent different
design strategies and have in part very different complexity. However, there is
no apparent relationship between fingerprint complexity and search performance.
In some cases, different fingerprints achieve very similar results. In others, per-
formance varies depending on the selectivity set. Furthermore, for target pairs,
fingerprint performance is frequently seen to vary depending on the search direc-
tion. Individual differences in fingerprint search performance often occur when
selective compounds are structurally heterogeneous, for example, in the case of
cathepsin inhibitors. Despite these compound set–dependent variations, differ-
ences in selectivity search performance between the fingerprints tested here are
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not dramatic. The two fingerprints of lowest complexity, MACCS and MP–MFP,
produce significant recovery rates comparable or higher than those obtained with
more complex designs. Overall, MOLPRINT 2D gives highest hit rates on target–
selective compounds and PDR–FP lowest (see also Appendix Table C.1). These
findings contrast the outcome of similarity search calculations on increasingly
structurally diverse compound activity classes where PDR–FP was often found to
perform best (Eckert and Bajorath [2006a]; Tovar et al. [2007]). Therefore, the re-
sults of activity– and selectivity–oriented similarity searching do not correspond to
each other. This means that molecular similarity relationships are likely to differ
within compound activity classes and selectivity sets and that recognizing com-
pounds with similar activity against a single target or detecting molecules with
different target selectivity challenges search methods in different ways. Clearly, a
characteristic feature of the presented search calculations is that target–selective
compounds are typically found in small database selection sets. Another im-
portant observation has been that in about half of the test cases recognition of
false–positive actives does not significantly increase when larger sets of database
compounds are selected. Thus, these calculations have notable specificity.
3.3 Analysis of Differential Selectivity Profiles
Based on the findings that 2D fingerprints are capable of differentiating between
compounds from pairwise selectivity sets, the study presented in this section inves-
tigated the performance of a wider spectrum of computational methods to study
different aspects of target selectivity. Compounds belonging to the same selectiv-
ity sets are now selective for one target over one or multiple other related other
ones, thereby allowing the analysis of selectivity in terms of an entire target fam-
ily. A systematic computational analysis of structure–selectivity relationships was
carried out on a refined biogenic amine GPCR dataset with different classification
methods and the results were compared compared to two previously studied 2D
fingerprints.
Calculation Setup
The 267 antagonists contained in the GPCRf database cover seven different recep-
tors belonging to three amine receptor subfamilies and display different selectivity
profiles for one receptor over several others, as is shown in Table 3.8.
For fingerprint searching, recursive partitioning (RP), and DynaMAD, 25 dif-
ferent reference sets from each selectivity set were randomly selected and 25 in-
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dependent calculations were carried out. The results were averaged. Reference
sets always consisted of half of the molecules in each selectivity set. The remain-
ing antagonists were added as potential hits to a subset of the ZINC7 database,
containing ∼3.7 million compounds. In each DynaMAD calculation, dimension
extension was continued over 20 dimension extension steps and hit and recovery
rates were monitored.
RP models were trained using the reference sets in the presence of differ-
ent sets of 500 randomly selected database molecules and used to search the
background database. Non–hierarchical Jarvis–Patrick (JP) and hierarchical–
agglomerative Ward’s clustering (WA) were applied to these selectivity sets in
the absence of background database compounds because these clustering meth-
ods are computationally expensive and it is difficult to use them for the analysis
of large databases. Furthermore, similarity search calculations using the MACCS
and MOLPRINT 2D fingerprints were performed on the basis of the Tanimoto
similarity coefficient and using multiple reference compounds in combination with
the 5NN nearest neighbor search strategy. For Ward’s clustering and RP, the
same pool of descriptors was used as for DynaMAD. Calculations for JP were
carried out using the MACCS keys fingerprint.
Performance of Clustering Methods
In order to estimate the degree of difficulty of distinguishing the structure–
selectivity relationships in the antagonist database, it was attempted to separate
the selectivity sets in the absence of background database compounds using stan-
dard clustering methods. The 267 antagonists were clustered using the JP and
WA algorithms together with MACCS keys and the pool of 155 1D/2D descrip-
tors, respectively. Smaller descriptor sets were also selected and evaluated on
the basis of feature significance and contingency analysis carried out with MOE.
JP clustering did not produce meaningful results. Different similarity and over-
lap settings produced between ca. 90 to 100 clusters dominated by singletons
and containing no more than three compounds. WA hierarchical clustering, that
has often shown better performance in the classification of molecules than non–
hierarchical clustering (Brown and Martin [1996]), produced better results that
are summarized in Appendix Table C.2. Here, different descriptor sets produced
comparable cluster compositions. For example, eight clusters at clustering level
three contained between eight and 53 compounds and were 33% - 100% pure.
However, seven of eight clusters combined antagonists from multiple selectivity
sets. Thus, even in the absence of database compounds, clustering of selectivity
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Selective for Over Size
5HT1a 5HT2a, Alpha1, D2 53
5HT2a 5HT1a, Alpha1, D1, D2 21
Alpha1 5HT1a, 5HT2a, D1, D2, D3, D4 26
D1 D2, D4 33
D2 5HT1a, D1, D3, D4 25
D3 D1, D2, D4 37
D4 Alpha1, D1, D2, D3 72
Table 3.8: Composition of the GPCRf database. This database contains seven compound
classes of selective GPCR antagonists. To be included in a compound selectivity set, an
antagonist is required to have at least 50–fold higher potency for one biogenic amine GPCR
over one or more others. For a detailed description see Appendix B.1.1.
sets was difficult suggesting that differentiating the underlying selectivity profiles
on the basis of molecular structure would be a non–trivial exercise.
Analysis of Similarity Search Calculations
Compared to a conventional virtual screen for compounds having similar activ-
ity, searching for target–selective compounds presents additional challenges. As
stated above, this is the case because GPCR antagonists must not only be distin-
guished from database decoys but also separated on the basis of their selectivity
profiles. Each of the selectivity sets consists of target–selective antagonists and
the combination of these sets can be regarded as an array of biogenic amine
GPCR family–selective compounds. Thus, selectivity searching, as described
herein, should ideally maximize the recall of target–selective and minimize the
recall of family–selective and background database compounds. Preferential de-
tection of family–selective compounds is in principle also a positive result, similar
to a conventional search for active compounds, but does not account for selec-
tivity at the level of individual targets, which represents the primary goal of this
investigation.
As already shown in the last section, 2D fingerprints displayed a tendency to
preferentially recognize selective molecules over database compounds when using
multiple selective reference compounds. Therefore, two fingerprints of different
design and complexity, MACCS and MOLPRINT 2D, were tested on the newly
assembled selectivity sets. Table 3.9 reports the results obtained for MACCS
and MOLPRINT 2D calculations. Both fingerprints successfully retrieved target–
selective molecules within the 100 top–scoring database compounds. Depending
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Target TSC FSC ZINC7 HR [%] RR [%]
5HT1a 11.6 1.0 87.4 11.6 43.1
5HT2a 5.6 0.1 94.3 5.6 51.3
Alpha1 7.9 0.0 92.1 7.9 60.6
D1 10.6 0.0 89.4 10.6 62.6
D2 6.0 0.0 94.0 6.0 45.9
D3 13.6 0.4 86.1 13.6 71.4
D4 12.3 0.4 87.4 12.3 34.1
(a) MACCS
Target TSC FSC ZINC7 HR [%] RR [%]
5HT1a 23.9 9.8 66.3 23.9 88.6
5HT2a 8.2 2.2 89.6 8.2 74.2
Alpha1 10.8 17.4 71.8 10.8 83.1
D1 16.0 1.0 83.0 16.0 93.9
D2 11.7 12.6 75.7 11.7 89.9
D3 18.1 4.8 77.2 18.1 95.2
D4 29.2 3.2 67.5 29.2 81.2
(b) MOLPRINT 2D
Table 3.9: Average results of 5NNMACCS and MOLPRINT 2D similarity search trials.
TSC and FSC stand for target– and family–selective compounds, respectively. For TSC, FSC,
and ZINC7, the average number of compounds among the top–scoring 100 compounds per
trial is reported. Hit and recovery rates are calculated for target–selective compounds.
on the selectivity set, MACCS achieved hit rates of up to 13.6% and recovery
rates of 71.4%. MOLPRINT 2D achieved hit rates of up to 29.2% and had consis-
tently high recovery rates ranging from greater than 70% to 95%. However, it can
be observed from Table 3.9 that MOLPRINT 2D recognized considerable num-
bers of family–selective antagonists, whereas MACCS essentially detected none.
For two classes, Alpha1 and D2, MOLPRINT 2D detected more family– than
target–selective compounds. Thus, although MOLPRINT 2D produced consis-
tently higher recall than MACCS, it was much less capable of differentiating be-
tween target– and family–selective antagonists. This is an interesting finding in
light of the low complexity of MACCS, which suggests that structural keys are
particularly attractive descriptors for selectivity analysis.
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Recursive Partitioning
Next, RP was investigated as a statistical compound classification technique that
can effectively process large numbers of descriptors and database compounds, in
contrast to standard clustering methods. For each set, 25 independently trained
RP models were used to search for antagonists in ZINC7. The best models pro-
duced top recall rates between 23% and 82% for the selectivity sets, but selected
also between 209 and 2 171 ZINC7 compounds, which resulted in maximal hit
rates between 0.4% and 3.3%. Average hit rates for all 25 models were lower than
1% for six of seven selectivity sets. Thus, in general, RP models selected too many
database compounds, which might in part be attributed to the relatively small
number of selective reference compounds available for model building.
Dynamic Compound Mapping
Then, the performance of compound mapping was evaluated. DynaMAD was
found to successfully discriminate between selective molecules and database com-
pounds and approached the overall performance of fingerprint searching. As
shown in Table 3.10, hit and recall rates of 5.2% to 21.1% and 21.5% to
45.9%, respectively, were observed. DynaMAD hit and recall rates were lower
than for MOLPRINT 2D, but DynaMAD hit rates were overall higher than for
MACCS. DynaMAD generally also recognized significantly more target– than
family–selective antagonist, except for D2 where more family–selective molecules
Target TSC FSC ZINC7 HR [%] RR [%] DEL Descr
5HT1a 8.5 0.1 85.4 9.0 31.4 9 47.6
5HT2a 2.4 0.0 26.3 8.2 21.5 6 25.8
Alpha1 3.6 0.0 66.0 5.2 28.0 5 24.4
D1 7.8 1.5 77.6 9.0 45.9 7 20.7
D2 3.9 8.9 48.9 6.4 30.2 6 17.7
D3 8.0 5.4 24.4 21.1 41.9 1 23.3
D4 12.5 1.0 61.8 16.6 34.8 14 90.1
Table 3.10: Average results of DynaMAD trials. TSC and FSC stand for target– and
family–selective compounds, respectively. For TSC, FSC, and ZINC7, the average number
of compounds per run is reported. Hit and recovery rate are calculated for target–selective
compounds. Results are reported for the dimension extension level (DEL) yielding a total
of 100 or fewer database compounds. Descr gives the number of descriptors at the reported
DEL, which is equivalent to the dimensionality of the chemical reference space for this mapping
step.
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were recognized. Overall, the ability of DynaMAD calculations to discriminate
target– and family–selective compounds was intermediate between MACCS and
MOLPRINT 2D. In contrast to fingerprint search calculations, DynaMAD does
not produce a ranking of database compounds according to similarity scores.
Rather, mapping statistics at different dimension extension levels determine the
number of database compounds that successfully match selective descriptor value
ranges. Therefore, dimension extension levels were chosen as reference points
for calculation of hit and recovery rates that retained fewer than 100 database
molecules, as shown in Table 3.10.
However, Appendix Table C.3 reports the corresponding results over all 20 di-
mension extension steps and Figure 3.7 shows a graphical representation of hit
rates over all dimension extension levels. As can be seen, for five of seven selectiv-
ity sets, DynaMAD calculations displayed a strong tendency to deselect database
compounds in increasingly high–dimensional descriptor spaces, that is, under
increasing mapping stringency, and preferentially retained selective molecules,
thereby producing hit rates approaching 100%. As reported in Appendix Table
C.3, compounds retained until the end of dimension extension were mostly, or
exclusively, target–selective. These observations suggest a search strategy for
practical applications when recall rates are not a primary measure of success and
it is more important to identify attractive new hits. Under these conditions,
DynaMAD calculations should be continued until only very few database com-
pounds remain. These might then have a high probability to contain molecules
with desired selectivity.
3.4 Design of Target–Selective Descriptor Spaces
As shown in the previous two sections, both DynaMAD and state–of–the–art fin-
gerprints display a tendency to detect target–selective compounds in screening
databases when selective reference molecules are used. These findings suggested
that selectivity differences between molecules that are active against related tar-
gets might be predictable using currently available similarity–based methods. As-
sessing compound selectivity is more demanding than normal similarity searching
because chemically related compounds with differential target activities have to
be distinguished, and thus the design of adequate chemical reference spaces is
of crucial importance. In order to investigate the feasibility of target–selective
chemical space design, a second generation DynaMAD–like mapping algorithm
termed CA–DynaMAD was developed and applied to the GPCRf database (see
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Figure 3.7: Average performance of DynaMAD. For each selectivity set, average
hit rates are monitored over all 20 dimension extension levels (DEL).
Appendix B.1.1 for a detailed description), containing molecules with experimen-
tally determined binding profiles against multiple closely related biogenic amine
GPCRs. Additionally, the performance of CA–DynaMAD and DynaMAD was
compared and analyzed.
Benchmark Calculations
For the comparison of DynaMAD and CA–DynaMAD, systematic test calculations
were carried out as follows. Each selectivity set was 100 times randomly divided
in half. One subset of the selective compounds was used as a reference set, while
the remaining compounds from the second subset were added to the the ZINC7
database as potential selective hits. In total, 100 independent search calculations
were carried out for each selectivity set and each calculation was terminated when
100 or fewer compounds in total remained.
Flexible Design of Target–Selective Spaces
In order to identify descriptor combinations that distinguish a selectivity set from
all others, each selectivity set was used once as a reference set and the remaining
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six sets as test compounds. CA–DynaMAD calculations were carried out until
the maximum number of these GPCR test compounds were eliminated through
addition of high–scoring reference set descriptors. The resulting descriptor combi-
nations form target–selective chemical reference spaces. Subsequently, the MDDR
database (see Appendix Chapter B.2) was mapped to the previously generated
target–selective descriptor spaces and the number of MDDR compounds matching
all selectivity set value ranges was determined. For each selectivity set, dimension
extension was then continued until 100 or 50 molecules remained. The ACTIVITY
and ACTION fields in the entries of all compounds in MDDR selection sets were
inspected to determine whether antagonists and target–selective hits were identi-
fied. Prior to this analysis, selectivity set compounds also present in the MDDR
were removed from the database.
Comparison of DynaMAD and CA–DynaMAD
For the comparison of CA–DynaMAD and DynaMAD, test calculations were car-
ried out on the seven compound selectivity sets. Akin to typical virtual screening
benchmark calculations, subsets of target–selective compounds were used as ref-
erence sets to search for the remaining selective molecules added to a background
database. For each selectivity set, a total of 100 independent search calculations
were carried out with varying reference set composition. Thus, a total of 1 400
search calculations were performed. In 1 376 of these trials, final database selec-
tion sets of 100 or fewer compounds contained correctly identified target–selective
molecules. DynaMAD calculations failed to recover selective compounds in 23 in-
dividual trials (four, six, and 13 for Alpha1, 5HT2a, and D2, respectively), whereas
CA–DynaMAD failed only in a single of its 700 trials (for Alpha1). A compari-
son of average results is shown in Figure 3.8. The effects of using a continuous
dimension extension and adaptive descriptor scoring on the dimensionality of the
final space representations can be observed in Figure 3.8a. For compound map-
ping using CA–DynaMAD, significantly fewer descriptors were required than for
DynaMAD, on average, only about a third. Figure 3.8b illustrates that hit rates
achieved with CA–DynaMAD and DynaMAD were overall comparable, despite
significant differences in the number of descriptors that were required. However,
as shown in Figure 3.8c, the recovery rates of selective compounds using CA–
DynaMAD were consistently higher. On average, about 25% more target–selective
compounds were recovered with CA–DynaMAD than with DynaMAD. This can
be rationalized by the achieved gradual reduction of database size through con-
tinuous dimension extension and adaptive descriptor scoring, thus reducing the
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number of potential hits lost during dimension extension. This is the case because
descriptors that discriminate most effectively between reference and database com-
pounds are re–determined at each step. Thus, the test calculations confirmed the
former expectations and the desired improvements of CA–DynaMAD over the
original DynaMAD implementation.
Generation of Target–Selective Descriptor Spaces
Next, the design of target–selective space representations using CA–DynaMAD
was investigated. In these calculations, compound mapping was carried out using
each complete selectivity set as a reference until the maximum number of com-
pounds belonging to the other selectivity sets was eliminated. For five of seven
selectivity sets, all other GPCR antagonists were eliminated, thus producing en-
tirely “pure” target–selective reference spaces. In the case of D4, a single 5HT1a
compound remained and vice versa. Thus, even for selectivity sets D4 and 5HT1a,
impurities were minute. Interestingly, only 29 of the 155 descriptors in our basis
set contributed to target–selective space representations. A summary of these
descriptors is provided in Table 3.11. Preferred descriptors included complex and
orthogonal designs of the BCUT (Pearlman and Smith [1998]) and VSA (Labute
[2004]) types, a number of topological indices, and even simple descriptors such
as the fraction of rotatable bonds or the number of double bonds in a molecule.
Of these 29 descriptors, 23 only contributed to one of seven target–selective space
representations and four to two. The balabanJ index and the SlogP VSA4 de-
scriptor occurred three and four times, respectively. Thus, only a small number of
property descriptors was required to successfully differentiate between GPCR an-
tagonists having different selectivity and the majority of these descriptors uniquely
contributed to different reference spaces. Table 3.12 reports the CA–DynaMAD
mapping statistics for each of the seven selectivity sets. As can be seen, only three
to eight descriptors were required to build target–selective space representations.
During dimension extension, GPCR antagonists belonging to other selectivity sets
were gradually eliminated. However, the top–scoring one or two descriptors made
the most significant contributions. In five cases, more than 70% of other GPCR
antagonists did not match the selectivity reference set value ranges of the first
descriptors. Thus, the respective descriptor value ranges were already signatures
of GPCR antagonist selectivity. For selectivity sets D2 and D3, the top–scoring
descriptors (BCUT PEOE 0 and KierA3, respectively) deselected more than 90%
of the other antagonists.
Taken together, these findings illustrate the ability of CA–DynaMAD calcu-
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(a)
(b)
(c)
Figure 3.8: Comparison of DynaMAD and CA–DynaMAD. Average results of 100
randomized search calculations are reported for each selectivity set. In (a), the number
of selected descriptors for DynaMAD and CA–DynaMAD calculations is given; (b) and
(c) report hit and recovery rates at the final dimension extension steps, respectively.
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Type Descriptor Explanation
Adjacency and distance balabanJ Balaban’s topological
matrix descriptors connectivity index
BCUT PEOE 0 BCUT–type descriptors for
BCUT PEOE 3 PEOE partial charges, SlogP
BCUT SLOGP 1 or molar refractivity (SMR)
BCUT SLOGP 3
BCUT SMR 0
GCUT PEOE 0 GCUT descriptors use graph
GCUT SLOGP 0 distances instead of bond order
GCUT SMR 0 information (like BCUTs)
VDistEq Distance matrix index
Atom and bond counts b 1rotR Fraction of rotatable bonds
b double Number of double bonds
lip don Number of OH and NH groups
Connectivity and shape chi1 Connectivity index
indices KierA3 Shape index
Partial charge descriptors PEOE VSA+0 Fractional polar van der Waals
PEOE VSA+1 surface area (vdW sa)
PEOE VSA FPPOS Fractional positive (vdW sa)
PEOE VSA HYD Total hydrophobic (vdW sa)
Molecular surface vsa acc Approximate sum of vdW
descriptors surface areas of hydrogen
bond acceptors
vsa pol Approximate sum of vdW
surface areas of polar atoms
Subdivided surface area SlogP VSA1 Combined with SlogP
descriptors SlogP VSA4
SlogP VSA5
SlogP VSA7
SMR VSA1 Combined with molar
SMR VSA2 refractivity (SMR)
SMR VSA4
SMR VSA6
Table 3.11: Descriptors for target–selective chemical spaces. Descriptors are
abbreviated and explained according to the Molecular Operating Environment and its
documentation material.
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lations to identify preferred descriptors for target–selective chemical space design
and compound classification.
Space Representations for Database Searching
Next, ∼160 000 MDDR compounds were mapped to the selectivity set value ranges
of the descriptors forming target–selective reference spaces. The results are re-
ported in Table 3.13. Only ∼1 000 to 7 000 MDDR compounds, depending on the
selectivity set, matched the descriptor value ranges of the target–selective spaces
(on average, ∼3 000 compounds). Thus, although these space representations were
low–dimensional and derived only on the basis of a total of 267 GPCR antago-
nists, they were already highly selective, accepting on average only less than 2%
of the MDDR, that contains ∼11 000 GPCR ligands (see Appendix B.2).
The dimensionality of the target–selective spaces was subsequently extended
in order to eliminate increasing numbers of MDDR compounds from them and de-
termine whether new target–selective compounds could be identified. Dimension
extension using CA–DynaMAD was continued until only small database selection
sets remained. It should be noted that dimension extension does not modify the
original selectivity of these spaces. All target–selective compounds remain selected
because they represent the reference set for continued dimension extension, and
all other GPCR antagonists used for space design remain deselected. However,
each additional dimension extension step eliminates a subset of database com-
pounds. The results for the last dimension extension steps are reported in Table
3.14. For six selectivity sets (except D4), database selection sets contained 50
or fewer MDDR compounds. For D4, 113 compounds remained because no dis-
criminatory descriptors were available to further reduce the number of database
compounds. In order to deselect nearly all MDDR compounds, the dimension-
ality of the original reference spaces needed to be in part significantly increased.
As reported in Table 3.14, addition of between five (D1) and 51 (D4) descriptors
was required. This was the case because random database compounds typically
have much broader value ranges than selectivity sets, which generally reduces
the discriminatory power of individual descriptors. Consequently, more descrip-
tors were required. However, through adaptive descriptor scoring, highly selective
chemical references spaces were obtained for each of the seven selectivity sets that
eliminated almost all MDDR compounds.
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Step Descriptor Deselection [%] Purity [%]
1 chi1 54.7 35.3
2 balabanJ 20.6 50.0
3 SMR VSA1 11.2 64.6
4 SlogP VSA1 6.1 76.8
5 PEOE VSA+0 3.3 85.5
6 GCUT PEOE 0 1.4 89.8
7 VDistEq 1.4 94.6
8 SlogP VSA4 0.9 98.2
(a) 5HT1a
Step Descriptor Deselection [%] Purity [%]
1 BCUT SLOP 3 76.4 26.6
2 PEOE VSA+1 11.8 42.0
3 SlogP VSA7 5.3 56.8
4 BCUT SLOGP 1 3.3 72.4
5 GCUT SMR 0 2.9 95.5
6 SMR VSA2 0.4 100.0
(b) 5HT2a
Step Descriptor Deselection [%] Purity [%]
1 vsa acc 85.5 42.6
2 SMR VSA4 12.4 83.9
3 b 1rotR 1.7 96.3
4 BCUT PEOE 3 0.4 100.0
(c) Alpha1
Step Descriptor Deselection [%] Purity [%]
1 BCUT SMR 0 74.8 35.9
2 SlogP VSA5 17.5 64.7
3 lip don 4.3 80.5
4 SMR VSA6 2.6 94.3
5 balabanJ 0.4 97.1
6 SlogP VSA4 0.4 100.0
(d) D1
Table 3.12: Generation of target–selective chemical space representations. Deselec-
tion reports the percentage of the total number of GPCR antagonists with different selectivity
that were eliminated through the addition of each descriptor. Purity gives the cumulative per-
centage of target–selective antagonists among all compounds passing the dimension extension
step.
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Step Descriptor Deselection [%] Purity [%]
1 BCUT PEOE 0 91.3 54.4
2 b double 6.2 80.7
3 vsa pol 2.5 100.0
(e) D2
Step Descriptor Deselection [%] Purity [%]
1 KierA3 93.5 71.2
2 GCUT SLOGP 0 4.8 90.2
3 SlogP VSA4 1.7 100.0
(f) D3
Step Descriptor Deselection [%] Purity [%]
1 PEOE VSA HYD 50.8 42.9
2 BCUT SLOGP 3 22.6 58.1
3 GCUT SMR 0 14.4 75.0
4 balabanJ 6.7 86.8
5 b 1rotR 3.1 93.6
6 SMR VSA4 1.0 96.0
7 SlogP VSA4 0.5 97.3
8 PEOE VSA FFPOS 0.5 98.6
(g) D4
Table 3.12: Continued.
Identification of Selective GPCR Antagonists
These small MDDR selection sets where then analyzed in order to determine
whether the CA–DynaMAD calculations identified selective GPCR antagonists.
Therefore, the biological annotation fields of all selected MDDR compounds were
studied. The results are summarized in Table 3.15. For each selectivity set, a
number of antagonists (between four and 44) with confirmed activity against the
selection set target were correctly detected but only for a total of 14 of these com-
pounds selectivity information was available. However, 13 of these 14 compounds
belonging to six selectivity sets were found to have correct selectivity profiles. Only
a single false–positive compound was found for D2 (with selectivity for 5HT1a over
D2 and Alpha1). Thus, reference spaces generated with CA–DynaMAD were suc-
cessfully applied to identify target–selective antagonists in the MDDR, suggesting
that these space representations might have considerable potential for practical
applications.
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Class
No. of
descriptors
No. of
MDDR compounds
5HT1a 8 1 096
5HT2a 6 1 397
Alpha1 4 7 418
D1 6 2 339
D2 3 2 651
D3 3 4 153
D4 8 1 914
Table 3.13: MDDR compounds in low–dimensional target–selective GPCR descriptor
spaces. Reported are the number of MDDR compounds that successfully mapped to each of
the initially created target–selective reference spaces.
Class Dimensionality
No. of
MDDR compounds
5HT1a 30 (+22) 49
5HT2a 14 (+8) 50
Alpha1 12 (+8) 45
D1 11 (+5) 47
D2 9 (+6) 44
D3 10 (+7) 48
D4 59 (+51) 113
Table 3.14: MDDR compounds in high–dimensional target–selective descriptor
spaces. The numbers in parentheses report the increase in dimensionality relative to the
original low–dimensional target–selective spaces.
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Class Identified antagonists Confirmed selective antagonists
5HT1a 22 (49) 1 [5HT1a over D1, D2, and 5HT2]
2 [5HT1a over Alpha1]
5HT2a 6 (50) 1 [5HT2a over Alpha1 and D2]
1 [5HT2a over 5HT1a, D4, and Alpha1]
Alpha1 9 (45) 1 [Alpha1 over D2 and 5HT2]
D1 11 (47) 1 [D1“over other GPCRs”]
1 [D1 over D2]
D2 4 (44) 1 [D2 over D3 and D4]
1 [for 5HT1a over D2 and Alpha1]
D3 5 (48) –
D4 44 (113) 3 [D4 over D2]
1 [D4 over 5HT1a and D2]
Table 3.15: Selective GPCR antagonists found in the MDDR. In the MDDR entries,
ACTIVITY fields were inspected to determine the number of correctly identified GPCR an-
tagonists (identified antagonists) among the total number of selected MDDR compounds (in
parentheses) and ACTION fields to obtain selectivity information (confirmed selective antag-
onists). The numbers of confirmed selective antagonists with different selectivity profiles are
given in bold and the selectivity profiles are reported in brackets. The profile of the only
antagonist with incorrect selectivity that was detected (for D2) is highlighted in italics. For
example, the row for 5HT1a needs to be interpreted as follows: 22 of 49 selected MDDR com-
pounds were designated 5HT1a antagonists (ACTIVITY) and for three of those, selectivity
information was provided (ACTION).
Chapter 4
Summary
In this thesis, ligand potency and selectivity were computationally analyzed using
2D molecular fingerprints and mapping algorithms. Biological screening data
were used to evaluate and confirm the suitability of 2D LBVS methods for dis-
criminating between active compounds with different potency. Then, two studies
established the general ability of 2D virtual screening methods to distinguish
between active compounds with different target–selectivity profiles at the target–,
sub–family– and family level. A dynamic mapping algorithm was designed capa-
ble of generating target–selective chemical reference spaces.
Chapter 3.1 reports the application of potency–directed similarity searching to
retrieve most potent hits from biological screening data. An approach is described
to incorporate compound potency as a parameter in similarity search calculations
in two conceptually different virtual screening methods. In both cases, a loga-
rithmic scaling function is used that assigns scaling factors to active compounds
according to their relative potency. In order to assess their potential for potency–
directed similarity searching, virtual screening calculations have been conducted
using a database of experimentally confirmed active and inactive compounds orig-
inating from an high–throughput screen for cathepsin B inhibitors. The structural
diversity among HTS hits spanning a relatively narrow and continuous potency
range and the similarity of active and inactive molecules made this screening set
a rather challenging test case for potency–scaled similarity analysis. However, it
provided a much more realistic and better defined benchmarking situation. In
general, narrow potency distributions and diverse active compounds are difficult
distinguish in potency–oriented molecular similarity calculations. By contrast,
the presence of discontinuous potency distributions over several orders of magni-
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tude and structural homogeneous subsets of highly and weakly potent compounds
makes it easy to direct search calculations toward the recognition of the most
potent database hits through potency scaling procedures. Given the features of
the cathepsin B HTS set as described, it was possible to ask two major questions
in this study: (a) can active molecules be recovered from this experimental set
through application of DMC and DACCS, and if so, (b) is it possible to enrich
selections with potent database compounds by incorporating ligand potency infor-
mation into these methods? In other words, can similarity calculations be directed
toward the recognition of potent hits when mining experimental screening data?
Although the biological screening data were challenging for the virtual
screening methods, DMC and DACCS calculations consistently retrieved ac-
tive molecules, in part, in very small selection sets. Both POT–DMC and
POT–DACCS calculations favored the recognition of potent hits and displayed a
tendency to deselect weakly potent ones, while retrieving similar or larger num-
bers of hits from the HTS data set compared to nonscaled calculations. Thus,
it can be concluded that potency scaling, as implemented in POT–DMC and
POT–DACCS, can successfully extrapolate from the features of potent reference
molecules and direct LBVS calculations toward the recognition of potent hits.
Molecular similarity methods are typically qualitative in nature, and POT–DMC
and POT–DACCS are the first similarity methods that explicitly consider rel-
ative compound potency during database searching. Since DMC and DACCS
are methodologically distinct, it is conceivable that potency scaling could also be
applied to similarity search tools or compound classification methods other than
these two algorithms.
In Chapter 3.2, a systematic study is presented that assesses the ability of
existing state–of–the–art 2D molecular fingerprints to distinguish between lig-
ands with different target selectivity. The selected fingerprints represent designs
of varying complexity and are based on structural fragments, connectivity pat-
terns, molecular property descriptors, or combinations thereof. The calculations
analyzed compounds selective for 13 targets belonging to the three families of
biogenic amine GPCRs, papain and chymotrypsin proteases, defining a set of 26
classes of compounds with selectivity for one target over another one.
Although selectivity search performance has only been moderate in some of
the test cases studied here, an interesting finding has been that essentially all
fingerprints tested displayed the potential to detect selective compounds in small
database selection sets, regardless of their design and complexity. The results of
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systematic similarity search calculations reveal that 2D fingerprints are capable
of identifying compounds having different selectivity against closely related target
proteins, although fingerprints were originally not developed for such applica-
tions. Selectivity search performance displayed a substantial compound class–
dependence, as has often been observed in similarity searching for active com-
pounds. Thus, it would be very difficult to predict which type of fingerprint to
use for a particular selectivity search application. A suitable strategy would be
to apply different fingerprints in parallel, which is further supported by the ob-
servation that essentially all fingerprints evaluated in this study had predictive
value. These findings also suggest that it might not necessarily be required to de-
velop conceptually novel computational methods to aid in chemical genetics and
genomics applications. Rather, existing methods might be adapted for such tasks.
In addition, the results indicate that different molecular similarity relationships
determine compound activity and target selectivity.
The finding that 2D fingerprints of markedly different complexity frequently
yield comparable performance in selectivity–oriented similarity searching expands
the scope and application radius of already established similarity–based methods
in chemoinformatics. As six of the compound classes originated from HTS data,
the corresponding experiments could be conducted under more realistic condi-
tions by using the confirmed inactives as screening database. Thus, it can be
anticipated that the findings of this study also hold true in real–world applications.
Based on the results reported in Chapter 3.2, the potential of fingerprint
searching and different compound classification methods to identify and distin-
guish between GPCR antagonists displaying seven different target selectivity pro-
files was explored as reported in Chapter 3.3. A refined database of selective
antagonists of biogenic amine GPCRs was used that enabled the study of target
selectivity with respect to an entire protein family.
The MACCS and MOLPRINT 2D fingerprints, which already had proven
their value for the identification of selective compounds in the previous study,
were selected and added to a set of compound classification methods, covering
standard algorithms like recursive partitioning as well as the recently introduced
DynaMAD approach.
Prior to virtual screening benchmark experiments, two clustering methods
were applied to group the GPCR antagonists according to their selectivity pro-
files. While JP clustering failed by mainly producing singletons, Ward’s clustering
provided better grouping but with limited cluster purity, suggesting that discrim-
86
inating between compounds with different selectivity profiles based on molecular
structure would not be trivial. RP calculations achieved acceptable recall rates
but failed to effectively distinguish active from database compounds. The anal-
ysis of the remaining methods revealed that the MACCS and MOLPRINT 2D
fingerprints and DynaMAD detected selective GPCR antagonists for most of
the test sets among reasonably sized selection sets. MACCS and DynaMAD
displayed the strongest tendency to preferentially identify target– over family–
selective compounds, while MOLPRINT 2D produced the overall highest recall of
family– and target–selective antagonists. This suggests that compound mapping
in high–dimensional chemical space representations has the potential to detect
subtle differences in closely related molecules that are selectivity determinants.
Moreover, it can be concluded that structural fragment–type descriptors are at-
tractive tools for the analysis of structure–selectivity relationships.
Finally, Chapter 3.4 reports on the design of target–selective chemical refer-
ence spaces generated by an advancement of the DynaMAD algorithm. The CA–
DynaMAD algorithm iteratively increases the dimensionality of reference spaces
in a controlled manner by evaluating a single molecular property descriptor per
iteration. The aim of this study was to evaluate whether the CA–DynaMAD
algorithm could be used to generate focused reference spaces facilitating the iden-
tification of active or selective compounds.
As could be shown in comparative VS calculations with DynaMAD, the im-
proved descriptor scoring and dimension extension function of CA–DynaMAD led
to an increase in compound recall while reducing the number of descriptor vari-
ables. Going beyond virtual screening, CA–DynaMAD was successfully applied
to design target–selective reference spaces for antagonists of seven biogenic amine
GPCRs. In a first step, the algorithm was applied only to the database of selec-
tive GPCR antagonists. For all seven antagonist classes, target–selective reference
spaces were designed such that nearly all antagonists could be correctly classified.
Subsequently, these reference spaces were used to successfully identify selective
compounds from a large biologically annotated database.
The design of appropriate chemical reference spaces is a key requirement
for many applications in chemoinformatics and computer–aided medicinal chem-
istry. Although the computational analysis and prediction of target selectivity
is more complicated than distinguishing active from inactive compounds, highly
resolved target–selective spaces that effectively deselected database compounds
were successfully derived and used to identify other target–selective GPCR an-
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tagonists. Therefore, the generation of target–selective reference spaces using CA–
DynaMAD complements and extends currently available approaches to chemical
space design. The utility of CA–DynaMAD to identify individual descriptors that
discriminate between antagonists with different selectivity has also been demon-
strated. Such descriptors can be used in many other computational applications,
for example, QSAR analysis. Taken together, these findings suggest that the de-
sign of “selectivity spaces” should merit further investigation and have significant
potential for practical applications.
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Symbols and Abbreviations
µ . . . . . . . . . . . . . . . . Arithmetic mean
σ . . . . . . . . . . . . . . . . Standard deviation
5HT1a/2a . . . . . . . 5–hydroxytryptamine (serotonin) receptors 1a/2a
ADME . . . . . . . . . . Absorption, distribution, metabolism, and excretion
Alpha1 . . . . . . . . . . Adrenaline receptor alpha1
CA–DynaMAD . . Continuous adaptive DynaMAD
Cat B, L, S, K . . . Cathepsin B, L, S, and K
D1-4 . . . . . . . . . . . . . Dopamine receptors 1-4
DACCS . . . . . . . . . . Distance in activity–centered chemical space
DEL . . . . . . . . . . . . . Dimension extension level
Descr . . . . . . . . . . . . Descriptors
DMC . . . . . . . . . . . . Dynamic mapping of consensus positions
DynaMAD . . . . . . . Dynamic mapping of activity–selective descriptor value ranges
ESS . . . . . . . . . . . . . Error sum of squares
FSC . . . . . . . . . . . . . Family–selective compounds
GPCR . . . . . . . . . . . G Protein–coupled receptor
HR . . . . . . . . . . . . . . Hit rate
HTS . . . . . . . . . . . . . High–throughput screening
IC50 . . . . . . . . . . . . . Inhibition concentration 50%, concentration of ligand that de-
creases enzyme activity by 50%
InChI . . . . . . . . . . . . IUPAC international chemical identifier
JP . . . . . . . . . . . . . . . Jarvis–Patrick clustering
Ki . . . . . . . . . . . . . . . Equilibrium dissociation constant, concentration of unlabeled
ligand at which it binds to half of the binding sites at equi-
librium in absence of competitors
LBVS . . . . . . . . . . . Ligand–based virtual screening
MACCS . . . . . . . . . Molecular access system
maxHR . . . . . . . . . . Maximum possible hit rate
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MDDR . . . . . . . . . . MDL drug data report
MOE . . . . . . . . . . . . Molecular Operating Environment
MP–MFP . . . . . . . . Median partitioning minifingerprint
PAC . . . . . . . . . . . . . Pair–active compounds
QSAR . . . . . . . . . . . Quantitative structure–activity relationship
RP . . . . . . . . . . . . . . Recursive partitioning
RR . . . . . . . . . . . . . . Recovery rate
SAR . . . . . . . . . . . . . Structure–activity relationship
SF . . . . . . . . . . . . . . . Scaling factor
SMILES . . . . . . . . . Simplified molecular input line entry specification
Tc . . . . . . . . . . . . . . . Tanimoto coefficient
TGT . . . . . . . . . . . . Typed graph triangle
TSC . . . . . . . . . . . . . Target–selective compounds
VS . . . . . . . . . . . . . . Virtual screening
WA . . . . . . . . . . . . . . Ward’s clustering
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Appendix A
Details on Molecular
Representations
A.1 Molecular Property Descriptors
The 1D and 2D molecular property descriptors used in the presented studies were
calculated using the Molecular Operating Environment (MOE). These 155 de-
scriptors can be divided into seven classes each of which contains between 12
and 33 descriptors as reported in Table A.1. The adjacency and distance matrix
descriptors are calculated from the connection table of a molecule and include
Balaban’s topological connectivity index (Balaban [1982]) and BCUT–type de-
scriptors (Pearlman and Smith [1998]) for PEOE partial charges (Gasteiger and
Marsili [1980]), SlogP or molar refractivity (Wildman and Crippen [1999]). The
Type Number of
descriptors
Adjacency and distance matrix descriptors 33
Atom and bond counts 33
Partial charge descriptors 30
Subdivided surface area descriptors 18
Physicochemical properties 13
Connectivity and shape indices 16
Molecular surface descriptors 12
Table A.1: Subset of 155 1D and 2D molecular property descriptors implemented in
MOE.
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occurrence of specific atom or bond types such as the number of rotatable bonds
is monitored by a set of atom and bond counts. Based on the method of partial
equalization of orbital electronegativities (PEOE) (Gasteiger and Marsili [1980]),
the partial charge descriptors like the total hydrophobic van der Waals surface
area account for the partial charge of each atom. Physicochemical property de-
scriptors include molecular density, molecular weight and logP(o/w). Subdivided
surface area descriptors as introduced by Labute [2004] combine physicochemi-
cal properties with the approximate accessible van der Waals surface area. The
connectivity and shape indices from Kier & Hall (Hall and Kier [1991]) are topolog-
ical descriptors intended to model different aspects of molecular shape. Finally,
molecular surface descriptors capture contributions of different atom types like
hydrogen bond donors or hydrogen bond acceptors to the van der Waals surface
area.
A.2 MDL MACCS keys
Developed for the purpose of substructure searching, the MDL MACCS keys were
introduced in 1979 and consist of 960 proprietary and 166 publicly available keys.
In this thesis, a fingerprint based on the public key set was used for similarity
searching and clustering. For all experiments presented in this thesis, MACCS
fingerprints have been calculated with MOE. Table A.2 lists all 166 keys as defined
and documented in MOE.
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Key Description
1 isotopes
2 atoms with atomic number >
103
3 group IVA, VA and VIA periods
4–6
4 Actinides
5 group IIIB, IVB elements
6 Lanthanides
7 group VB, VIB, VIIB elements
8 heteroatoms in 4–membered
rings
9 group VIIIB elements
10 alkaline earth elements
11 atoms in 4–membered ring
12 group IB, IIB elements
13 N connected to 1 O and 2 C
14 S atoms in S-S groups
15 C connected to 3 O
16 heteroatoms in 3–membered
rings
17 C in CC triple bonds
18 group IIIA elements
19 atoms in 7 ring
20 silicon atoms
21 C = bonded to C and 3 heavy
atoms
22 atoms in 3 ring
23 C bonded 1 N and 2 O
24 O-N single bonds
25 C bonded to at least 3 N atoms
26 C in 3 ring bonds and a double
bond
27 iodine atoms
28 XCH2X, where X<>C
29 phosphorous atoms
30 non–C Q4 bonded to ≥ 3 C
31 halogens connected to non–
carbons
32 S bonded to an N and a C
33 S atoms bonded to N
34 CH2= units
Key Description
35 alkali (group IA ) elements
36 S atoms in rings
37 C bonded to ≥ 1 O & ≥2 N
38 C bonded ≥ 2 N and 1 C
39 S atoms bonded to 3 O
40 S single bonded to OQ2
41 N in CN
42 fluorine atoms
43 X-H heteroatoms 2 bonds from
another
44 other elements
45 N atoms adjacent to -C=C
46 bromine atoms
47 S two bonds from an N
48 non–C bonded to ≥ 3 O
49 charged atoms
50 C in C=C bonded to ≥ 3 C
51 S bonded to a C and an O
52 N bonded to N
53 QH 4 bonds from another QH
54 QH 3 bonds from another QH
55 S bonded to ≥2 O
56 N bonded to ≥ 2 O and ≥ 1 C
57 O in rings
58 S bonded to ≥2 non–carbon
atoms
59 non–aromatic S-[a]
60 [S+]-[O-]
61 SQ3
62 non–ring bonds that connect
rings
63 N atoms in double bonds with
O
64 non–ring S attached to a ring
65 N in aromatic bonds with C
66 CX4 bonded to ≥3 carbons
67 S attached to heteroatoms
68 QH bonded to another QH
69 QH bonded to another Q
70 N bonded to two non–C heavy
atoms
Table A.2: Publicly available set of 166 MACCS keys.
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Key Description
71 N bonded to O
72 O separated by 3 bonds
73 S in double/charge separated
bonds
74 dimethyl substituted atoms
75 N non–ring bonded to a ring
76 C in C=C bonded to ≥ 3 heavy
atoms
77 N separated by 2 bonds
78 N double bonded to C
79 N separated by 3 bonds
80 N separated by 4 bonds
81 S attached to Q ≥ 3 atoms
82 heteratoms attached to a CH2
83 heteroatoms in 5 ring
84 NH2 groups
85 N bonded to ≥ 3 C
86 CH2 or CH3 separated by non–
C
87 halogens bonded to any ring
88 sulfurs
89 O separated by 4 bonds
90 het. 3 bonds from a CH2
91 het. 4 bonds from a CH2
92 C bonded to ≥1 N, ≥1 C & ≥
1 O
93 methylated heteroatoms
94 N bonded to non–C
95 O 3 bonds from an N
96 atoms in 5–rings
97 O 4 bonds from an N
98 het. in 6–ring
99 C in C=C
100 N attached to CH2
101 atoms in 8–ring or higher
102 O bonded to non–C heavy
atoms
103 chlorine atoms
Key Description
104 hets. 2 bonds from a CH2
105 hets. ring bonded to a 3–ring
bond X
106 X bonded to ≥ 3 non–C
107 XQ>3 bonded to at least 1
halogen
108 CH3 4 bonds from a CH2
109 O attached to CH2
110 O 1 C from an N
111 N 2 bonds from a CH2
112 atoms with coordination num-
ber ≥ 4
113 O in non–aromatic bonds to an
[a]
114 CH3 attached to CH2
115 CH3 2 bonds from a CH2
116 CH3 3 bonds from a CH2
117 N 2 bonds from an O
118 (key(147)-1 if key(147)>1;
else 0)
119 N in double bonds
120 (key(137)-1 if key(137)>1;
else 0)
121 N in rings
122 N with coordination number
≥3
123 O separated by 1 C
124 het-het bonds
125 Is AROMATIC RING > 1?
126 non–ring O bonded to 2 heavy
atoms
127 (key(143)-1 if key(143)>1;
else 0)
128 CH2s separated by 4 bonds
129 CH2s separated by 3 bonds
130 (key(124)-1 if key(124)>1;
else 0)
131 ( het atoms with H)
Table A.2: Continued.
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Key Description
132 O 2 bonds from CH2
133 N non–ring bonded to a ring
134 halogens
135 N in a non–aromatic bond with [a]
136 Bit: is there more than 1 O=
137 Total ring HETEROCYCLE atoms
138 (key(153)-1 if key(153)>1; else 0)
139 OH groups
140 (key(164)-3 if key(164)>3; else 0)
141 (key(160)-2 if key(160)>2; else 0)
142 (key(161)-2 if key(161)>1; else 0)
143 non–ring O connected to a ring
144 atoms separated by (!:):(!:)
145 6M RING > 1
146 Key(164)-2 if key(164)>2; else 0
147 CH2 attached to CH2
148 non–C with coordination number ≥3
149 (key(160)-1 if key(160)>1; else 0)
150 X separated by (!r)-r-(!r)
151 NH
152 C bonded to ≥2 C and 1 O
153 non–carbons attached to CH2
154 O in C=O
155 non–ring CH2
156 XN where coord. of X≥3
157 O in C-O single bonds
158 N in C-N single bonds
159 Key(164)-1 if key(164)>1; else 0
160 CH3 groups
161 N
162 aromatics
163 atoms in 6 rings
164 oxygens
165 ring atoms
166 Is there more than 1 fragment?
Table A.2: Continued.
Appendix B
Compound Databases
B.1 Classes of Selective Compounds
B.1.1 Biogenic Amine GPCR Antagonists
In this thesis, two molecular benchmark systems consisting of antagonists of bio-
genic amine binding G protein–coupled receptors (GPCRs) are used to study
compounds with different selectivity profiles and evaluate 2D similarity methods
for their potential to detect selectivity differences between these closely related
molecules.
GPCRs form a large protein superfamily that plays an important role in
many physiological and patho–physiological processes and, currently, presents the
largest group of pharmaceutical targets (Klabunde and Hessler [2002]; Overington
et al. [2006]). In particular, the subfamily of biogenic amine binding GPCRs has
provided attractive drug targets for the treatment of various neurological and car-
diological diseases (Overington et al. [2006]). In computer–aided drug discovery,
these GPCRs have traditionally been major targets for ligand design based on
pharmacophore analysis (Klabunde and Evers [2005]). As summarized in Table
B.1, targeted receptors belong to three major amine receptor subfamilies, the
dopaminergic, serotonergic, and adrenergic GPCR subfamilies. The databases
contain only competitive and reversible antagonists or partial agonists and gener-
ally share a canonical molecular organization where arylpiperazine or piperidine
moieties are connected through alkyl or alkenyl spacers to heteroaromatic systems
(Stumpfe et al. [2007]). Variations in these structural motifs are responsible for
differences in ligand selectivity. For computational approaches, distinguishing be-
tween compounds having limited structural diversity, but significant differences
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Superfamily Family Subfamily Targets
Rhodopsin–like Biogenic amine Adrenergic Alpha1
GPCRs GPCRs Dopaminergic D1, D2, D3, D4
Serotonergic 5HT1a, 5HT2a
Table B.1: Biogenic amine G protein–coupled receptor.
in selectivity is thought to be a challenging task. The two databases of selective
biogenic amine GPCR antagonists, GPCRpw and GPCRf , differ in the way how
selectivity profiles are captured and how individual selectivity sets are constituted.
GPCRpw This database was introduced by Stumpfe et al. [2007] and contains
248 compounds with antagonistic activity against at least two of six targets be-
longing to the family of biogenic amine GPCRs. Based on differences in their po-
tency against multiple receptors, these compounds are grouped into 12 classes of
antagonists with selectivity for one receptor over another one. Thus, the GPCRpw
permits to study differential selectivity considering two targets at once on the ba-
sis of pairwise selectivity sets. A compound is considered selective for a given
target if its Ki or IC50 value is at least 50–fold lower than for targets within the
same subfamily. As shown in Table B.2, sets from this database contain between
nine and 64 compounds, spanning a considerable range in target selectivity. The
intra– and inter–set MACCS Tc similarity is visualized in Figure B.1 and the
analysis reveals a generally higher degree of similarity compared to the protease
inhibitor sets described further below. However, comparison of selectivity sets for
target pairs shows rather different diversity patterns (for example, Figures B.1a
and B.1d). Similarly, the scaffold diversity measured by the ratio of chemical
scaffolds over the total number of compounds per set varies significantly.
APPENDIX B. COMPOUND DATABASES 109
D1 D2
(a)
D1 D4
(b)
D4 D2
(c)
D2 5HT1a
(d)
Figure B.1: MACCS Tc analysis of GPCRpw selectivity sets. MACCS Tc values
are reported in matrix format for systematic intra–set and inter–set pairwise com-
pound comparisons in (a) - (f). The values are color–coded according to following
scheme: dark green 0-0.2, light green 0.2-0.4, yellow 0.4-0.6, orange 0.6-0.8, red 0.8-
1. Compound sets with“bidirectional” selectivity are compared. For example, the D1
versus D2 matrix in (a) compares D1 compounds selective over D2 and vice versa.
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D3 D4
(e)
5HT1a Alpha1
(f)
Figure B.1: Continued.
Selective for Over Size Selectivity Scaffold Diversity
5HT1a
Alpha1 46 55 - 10 000 0.70
D2 24 58 - 10 000 0.88
Alpha1 5HT1a 27 59 - 20 000 0.67
D1
D2 31 59 - 10 084 0.55
D4 13 65 - 4 761 0.39
D2
D1 26 67 - 18 310 0.54
D4 9 50 - 834 0.33
5HT1a 11 50 - 1 628 0.27
D3 D4 12 51 - 1 609 0.92
D4
D1 20 190 - 30 769 0.45
D2 64 59 - 17 600 0.33
D3 33 52 - 15 000 0.64
Table B.2: Pairwise selective antagonist classes in GPCRpw. Selectivity gives the range
of potency ratios that are a quantitative measure of selectivity for the corresponding target.
Scaffold Diversity reports the ratio of chemical scaffolds over the total number of compounds
per set. Chemical scaffolds were calculated by deleting all non–ring substituents except linkers
between ring systems.
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GPCRf The second biogenic amine GPCR database extends GPCRpw and
shifts the analysis of differential compound selectivity profiles from related target–
pairs to an entire target family. It contains 267 selective antagonists distributed
among seven receptor selectivity sets. All compounds have at least 50-fold higher
potency for one biogenic amine GPCR over one or more others. Table B.3 shows
that antagonists in the selectivity sets cover large selectivity ranges, spanning sev-
eral orders of magnitude. Figure B.2 illustrates a part of the structural spectrum
of antagonists in GPCRf with different selectivity. The structures of antagonists
displaying different selectivity profiles are often topologically similar but each of
the selectivity sets contains compounds representing multiple scaffolds. There are
differences in molecular size and rigidity of chemotypes within and between se-
lectivity sets. Intra– and inter–set structural similarity is generally comparable,
as revealed by systematic pairwise MACCS Tc compound comparisons reported
in Table B.4, supplemented by Figure B.3. Overall, the antagonists represent
a rather continuous structural spectrum with varying and in part overlapping
selectivity relationships. These characteristics make it generally difficult to sys-
tematically distinguish between compounds having different selectivity and hence
these selectivity sets present difficult test cases for differentiating the underlying
structure–selectivity relationships.
Selective for Over Size Selectivity Scaffold diversity
5HT1a 5HT2a, Alpha1, D2 53 65 - 476 190 0.53
5HT2a 5HT1a, Alpha1, D1,
D2
21 67 - 49 122 0.38
Alpha1 5HT1a, 5HT2a, D1,
D2, D3, D4
26 59 - 62 500 0.81
D1 D2, D4 33 55 - 10 084 0.42
D2 5HT1a, D1, D3, D4 25 73 - 18 310 0.36
D3 D1, D2, D4 37 51 - 17 600 0.70
D4 Alpha1, D1, D2, D3 72 54 - 28 000 0.38
Table B.3: Selective GPCR antagonist classes in GPCRf . Selectivity gives the range
of potency ratios that are a quantitative measure of selectivity for the corresponding target.
Scaffold Diversity reports the ratio of chemical scaffolds over the total number of compounds
per set. Chemical scaffolds were calculated by deleting all non–ring substituents except linkers
between ring systems.
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Figure B.2: Representative structures of selective GPCR antagonists from
GPCRpw. At the top left and right, the most selective 5HT1a and Alpha1 antago-
nists are shown, respectively. In addition, antagonists from other selectivity sets with
varying degrees of similarity to these highly selective compounds are shown. This rep-
resentative overview illustrates a part of the structural spectrum of GPCR antagonists
with different selectivity.
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Selectivity set 5HT1a 5HT2a Alpha1 D1 D2 D3 D4
5HT1a Min 0.39 0.35 0.36 0.28 0.34 0.37 0.34
Max 1.00 0.82 1.00 0.74 0.80 0.85 0.97
Mean 0.64 0.53 0.58 0.51 0.58 0.53 0.58
5HT2a Min 0.35 0.37 0.34 0.29 0.37 0.33 0.34
Max 0.82 1.00 0.85 0.72 0.78 0.76 0.79
Mean 0.53 0.59 0.52 0.48 0.54 0.49 0.53
Alpha1 Min 0.36 0.34 0.40 0.32 0.39 0.34 0.40
Max 1.00 0.85 1.00 0.80 0.84 0.85 0.89
Mean 0.58 0.52 0.67 0.56 0.55 0.58 0.59
D1 Min 0.28 0.29 0.32 0.31 0.33 0.31 0.30
Max 0.74 0.72 0.80 1.00 0.81 0.70 0.71
Mean 0.51 0.48 0.56 0.64 0.50 0.50 0.52
D2 Min 0.34 0.37 0.39 0.33 0.40 0.37 0.37
Max 0.80 0.78 0.84 0.81 1.00 0.77 0.82
Mean 0.58 0.54 0.55 0.50 0.62 0.50 0.55
D3 Min 0.37 0.34 0.40 0.30 0.37 0.38 0.34
Max 0.85 0.79 0.89 0.71 0.82 1.00 0.83
Mean 0.53 0.53 0.59 0.52 0.55 0.61 0.54
D4 Min 0.34 0.34 0.40 0.30 0.37 0.34 0.38
Max 0.97 0.79 0.89 0.71 0.82 0.83 1.00
Mean 0.58 0.53 0.59 0.52 0.55 0.54 0.63
Table B.4: Intra– and inter–set compound similarity of GPCRf set measured by
pairwise MACCS Tc values. Intra–set similarity values are given in bold.
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5HT1a
5HT2a
Alpha1
D1
D2
D3
D4
Figure B.3: MACCS Tc matrix of GPCRf . MACCS Tc values are reported in
matrix format for systematic intra–set and inter–set pairwise compound comparisons.
The values are color–coded according to following scheme: dark green 0-0.2, light
green 0.2-0.4, yellow 0.4-0.6, orange 0.6-0.8, red 0.8-1.
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B.1.2 Selective Cathepsin Inhibitors
For four members belonging to the C1 papain–like family, the lysosomal cysteine
proteases cathepsins B, L, S, and K, a number of active compound classes could
be built from publicly available sources. For cathepsins B, L, and S, biological
screening data are available from three different HTS campaigns carried out at
the Penn Center for Molecular Discovery at the University of Pennsylvania1, made
public through PubChem2. In addition, 45 selective inhibitors for cathepsin S and
K were gathered from literature and database sources as described in Stumpfe
et al. [2007].
Superfamily Family Subfamily Targets
Papain–like thiol C1 Papain Cat B–like Cat B
proteases Cat L–like Cat L, S, K
Table B.5: Lysosomal cysteine proteases.
The cathepsin HTS data set used for the study of selectivity profiles was ob-
tained by merging the results of the three screens for inhibitors of cathepsins B,
L and S, respectively. As shown in Table B.9, the intersection of these three dif-
ferent assays consists of 55 134 compounds including 79 hits with confirmed IC50
below 45 µM against only one of the targets. Figure B.4 enables the assessment
of pairwise–similarity among confirmed HTS hits and inactives. It can clearly be
seen that the similarity between active compounds is comparable to the similar-
ity between actives and inactives, as would be expected from HTS results. As
reported in Table B.6, the scaffold diversity is overall greater than for the prior
described GPCR classes.
As shown in Figure B.5, inter–set similarity of cathepsin HTS hits is quite
heterogeneous. Intra–set similarity of cathepsin B and L is overall lower than for
cathepsin S HTS hits. Comparison of compound sets gathered from literature
sources shows different patterns of slightly higher similarity (see Figure B.5b).
Overall, the cathepsin L set is structurally most diverse.
1The Penn Center for Molecular Discovery (PCMD).
http://www.seas.upenn.edu/~pcmd/
2PubChem BioAssay Summaries AID 453, 460, and 501
http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=453
http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=460
http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=501
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Selective for Over Size Selectivity Scaffold Diversity
Cat B
Cat L 23 HTS specific 0.70
Cat S 23 HTS specific 0.70
Cat L
Cat B 33 HTS specific 0.91
Cat S 33 HTS specific 0.91
Cat S
Cat B 23 HTS specific 0.78
Cat L 23 HTS specific 0.78
Cat K 20 65 - 119 298 0.95
Cat K Cat S 25 50 - 1 000 0.88
Table B.6: Pairwise–selective cathepsin sets. Selectivity reports potency ratios for com-
pounds from the literature. HTS specific means that active compounds come from HTS data
and showed measurable activity against only one target. Scaffold diversity reports the ratio
of chemical scaffolds over the total number of compounds per set.
Figure B.4: Cat BLS HTS Tc similarity. Histogram of pairwise Tc similarity based
on MACCS keys fingerprint. Number of occurrences of MACCS Tc values among
actives and between actives and inactives are colored in red and gray, respectively.
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Cat B Cat L Cat S
(a)
Cat S Cat K
(b)
Figure B.5: MACCS Tc matrices of cysteine protease inhibitors. MACCS Tc
values are reported in matrix format for systematic intra–set and inter–set pairwise
compound comparisons in (a) and (b). The values are color–coded according to
following scheme: dark green 0-0.2, light green 0.2-0.4, yellow 0.4-0.6, orange 0.6-
0.8, red 0.8-1.
B.1.3 Serine Inhibitor Classes
As shown in Table B.7, the second database of selective protease inhibitors tar-
gets three members of the S1 chymotrypsin family, namely trypsin, thrombin,
and factor Xa. The six pairwise selectivity sets contain between 20 to 52 com-
pounds with significant selectivity for one target over another one and originate
from a considerable variety of chemical scaffolds (Table B.8). The significantly
different diversity patterns for selectivity sets and their comparison in Figure B.6
demonstrate that there is no obvious correlation between structural similarity or
diversity and compound selectivity. Both thrombin and trypsin inhibitors that
are selective over factor Xa have significant intra–set similarity. By contrast,
thrombin inhibitors selective over trypsin are structurally heterogeneous. Struc-
turally similar compounds, but also structurally diverse compounds, are found to
be target–selective and compounds having opposite selectivity are often related
by different degrees of structural diversity.
B.1. CLASSES OF SELECTIVE COMPOUNDS 118
Superfamily Family Subfamily Targets
Chymotrypsin–like S1 Chymotrypsin Trypsin–like Thrombin, Trypsin,
serine proteases Factor Xa
Table B.7: Trypsin–like serine proteases.
Selective for Over Size Selectivity Scaffold Diversity
Thrombin
Trypsin 35 103 - 122 059 1.00
Factor Xa 52 100 - 490 000 0.64
Trypsin
Thrombin 20 100 - 11 428 0.65
Factor Xa 25 100 - 100 000 0.72
Factor Xa
Thrombin 48 104 - 200 000 0.55
Trypsin 49 100 - 400 000 0.79
Table B.8: Pairwise selective serine inhibitor classes. Selectivity gives the range of
potency ratios that are a quantitative measure of selectivity for the corresponding target.
Scaffold Diversity reports the ratio of chemical scaffolds over the total number of compounds
per set.
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Factor Xa Thrombin
(a)
Factor Xa Trypsin
(b)
ThrombinTrypsin
(c)
Figure B.6: MACCS Tc matrices of serine protease inhibitors. MACCS Tc
values are reported in matrix format for systematic intra–set and inter–set pairwise
compound comparisons in (a) - (c). The values are color–coded according to following
scheme: dark green 0-0.2, light green 0.2-0.4, yellow 0.4-0.6, orange 0.6-0.8, red 0.8-1.
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B.2 Screening Databases
To verify and benchmark methods for ligand–based virtual screening, the avail-
ability of an adequate screening database is of crucial importance. Ideally, such
a database is biologically annotated, that is, information on biological activity in
general or with respect to a given target is available for each compound. However,
as such information must be experimentally determined, benchmark experiments
aiming at differentiating active from inactive compounds often employ databases
of up to several millions of drug–like compounds for which no biological activ-
ity information is given, but which are considered inactive. In the following, the
screening databases employed for the presented studies are listed, ranging from ex-
perimentally confirmed HTS data for selected targets to databases of compounds
without or with incomplete activity information.
B.2.1 Inactive HTS Compounds
From the biological screening data of three HTS campaigns for inhibitors of
cathepsins B, L, and S, conducted at the Penn Center for Molecular Discovery
at the University of Pennsylvania3, made public through PubChem4, the con-
firmed inactive compounds were extracted. As all three campaigns used a largely
overlapping screening database, it was possible to generate a database of 55 055
compounds inactive (IC50 ≥ 50µM) against all three targets. This database was
used for the study of selectivity profiles reported in Chapter 3.2. The number of
confirmed inactive compounds is reported in Table B.9.
Target No. of compounds
Cathepsin B 63 292
Cathepsin L 57 773
Cathepsin S 61 995
intersection 55 055
Table B.9: Inactive HTS compounds. All compounds in the reported sets have an IC50
value above 50 µM against the respective target.
3The Penn Center for Molecular Discovery (PCMD).
http://www.seas.upenn.edu/~pcmd/
4The PubChem Project
http://pubchem.ncbi.nlm.nih.gov/
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B.2.2 MDL Drug Data Report
The MDL Drug Data Report5 (MDDR) is a biologically annotated compound
database covering the patent literature, journals, and congresses. The herein re-
ported experiments use version 2005.2, containing 161 845 compounds with unique
2D structure with a wide variety of biological targets. According to the biolog-
ical activity annotation, there are ∼5.9k GPCR antagonists and ∼5.2k GPCR
agonists, approximately 3.7% and 3.2% of the entire database, respectively.
B.2.3 ZINC
During the course of the studies reported in this thesis two different subsets of the
ZINC database (Irwin and Shoichet [2005]), provided by the Shoichet Laboratory
at the Department of Pharmaceutical Chemistry at the University of California,
San Francisco (UCSF)6, were used as databases of assumed inactive compounds for
virtual screening experiments. The first database contains 1 442 389 compounds
with unique 2D structure from the drug–like set of ZINC6. The second database
is a subset of the current version ZINC7 and contains 3 695 953 compounds with
unique 2D structure. It was generated by applying a reactivity filter and a broad
Lipinski rule filter as defined in Table B.10.
Property Range
Molecular weight 0 - 600
logP -2 - 6
Hydrogen bond donors 1 - 10
Hydrogen bond acceptors 1 - 10
Rotatable bonds 0 - 18
Table B.10: Lipinski–like filter applied to the ZINC7 database.
5MDL Drug Data Report, Symyx Software: San Ramon, CA.
http://www.mdli.com/products/knowledge/drug_data_report/
6ZINC - a free database of commercially available compounds for virtual screening
http://zinc.docking.org/
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Appendix C
Calculation Data
C.1 Similarity Search Results
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Figure C.1: Retrieval of selective compounds. In (a)-(l), the average recovery of
hits in selection sets of increasing size, ranging from 5 to 100 database compounds, is
reported. The leftmost data points correspond to the smallest selection set size of five
compounds; then, set sizes increase in increments of five compounds. The graphical
representations monitor the retrieval of target–selective versus pair–active compounds,
as defined in the text. The total number of recovered pair–active compounds is
reported (top horizontal axis) and also the rate (bottom). The vertical axis reports
the ratio of target–selective over pair–active compounds.
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Figure C.1: Continued.
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Figure C.1: Continued.
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Figure C.1: Continued.
C.1. SIMILARITY SEARCH RESULTS 128
MP–MFP
PDR–FP
MOLPRINT 2D
TGT
MACCS
Number of recovered pair–active compounds
5HT1a/Alpha1
Recovery of pair–active compounds
R
at
io
of
ta
rg
et
–s
el
ec
ti
ve
co
m
p
ou
n
d
s
151050
0.30.250.20.150.10.050
1
0.9
0.8
MP–MFP
PDR–FP
MOLPRINT 2D
TGT
MACCS
Number of recovered pair–active compounds
Alpha1/5HT1a
Recovery of pair–active compounds
R
at
io
of
ta
rg
et
–s
el
ec
ti
ve
co
m
p
ou
n
d
s
1050
0.20.150.10.050
1
0.9
0.8
(f)
Figure C.1: Continued.
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Figure C.1: Continued.
C.1. SIMILARITY SEARCH RESULTS 130
MP–MFP
PDR–FP
MOLPRINT 2D
TGT
MACCS
Number of recovered pair–active compounds
Factor Xa/Trypsin
Recovery of pair–active compounds
R
at
io
of
ta
rg
et
–s
el
ec
ti
ve
co
m
p
ou
n
d
s
20151050
0.350.30.250.20.150.10.050
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
MP–MFP
PDR–FP
MOLPRINT 2D
TGT
MACCS
Number of recovered pair–active compounds
Trypsin/Factor Xa
Recovery of pair–active compounds
R
at
io
of
ta
rg
et
–s
el
ec
ti
ve
co
m
p
ou
n
d
s
151050
0.30.250.20.150.10.050
1
0.9
0.8
0.7
0.6
0.5
(h)
Figure C.1: Continued.
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Figure C.1: Continued.
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Figure C.1: Continued.
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Figure C.1: Continued.
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Figure C.1: Continued.
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Figure C.2: Ratio of false–positive active versus target–selective compounds.
The bar graphs shown in (a)-(w) report the relative amounts of false–positive active
(light gray) and target–selective (dark gray) compounds for each fingerprint method
as an average number of these compounds in differently sized selection sets ranging
from 50 to 550 compounds. According to the definition in the text, the sum of
false–positive active and target–selective molecules are pair–active compounds. Total
numbers of pair–active compounds are reported in parentheses.
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Figure C.2: Continued.
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Figure C.2: Continued.
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Figure C.2: Continued.
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Figure C.2: Continued.
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Figure C.2: Continued.
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Figure C.2: Continued.
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Figure C.2: Continued.
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Figure C.2: Continued.
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Figure C.2: Continued.
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Figure C.2: Continued.
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Figure C.2: Continued.
APPENDIX C. CALCULATION DATA 147
50 200 350 500
Active compounds (29)
D2/5HT1a (5)
MACCS
Selection sets
Av
er
ag
e 
nu
m
be
r o
f r
ec
ov
er
ed
 a
ct
ive
s
0
2
4
6
8
50 200 350 500
Active compounds (29)
D2/5HT1a (5)
MOLPRINT 2D
Selection sets
Av
er
ag
e 
nu
m
be
r o
f r
ec
ov
er
ed
 a
ct
ive
s
0
2
4
6
8
50 200 350 500
Active compounds (29)
D2/5HT1a (5)
MP−MFP
Selection sets
Av
er
ag
e 
nu
m
be
r o
f r
ec
ov
er
ed
 a
ct
ive
s
0
2
4
6
8
50 200 350 500
Active compounds (29)
D2/5HT1a (5)
PDR−FP
Selection sets
Av
er
ag
e 
nu
m
be
r o
f r
ec
ov
er
ed
 a
ct
ive
s
0
2
4
6
8
50 200 350 500
Active compounds (29)
D2/5HT1a (5)
TGT
Selection sets
Av
er
ag
e 
nu
m
be
r o
f r
ec
ov
er
ed
 a
ct
ive
s
0
2
4
6
8
(m)
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MACCS PAC [%] TSC [%]
maxHR HR RR maxHR HR RR
D1/D2 47.0 14.4 30.7 21.0 12.2 57.9
D2/D1 47.0 7.3 15.6 16.0 7.0 43.5
D1/D4 27.0 2.8 10.2 7.0 2.8 39.4
D4/D1 27.0 9.4 34.8 14.0 9.4 67.1
D2/D4 68.0 3.7 5.4 4.0 3.7 93.0
D4/D2 68.0 12.4 18.3 59.0 12.4 21.1
D3/D4 39.0 4.4 11.4 6.0 4.4 72.7
D4/D3 39.0 9.5 24.3 27.0 9.4 35.0
D2/5HT1a 29.0 4.3 14.8 5.0 4.3 85.6
5HT1a/D2 29.0 9.6 33.1 18.0 9.6 53.3
Alpha1/5HT1a 63.0 11.0 17.5 17.0 11.0 65.0
5HT1a/Alpha1 63.0 12.0 19.1 36.0 12.0 33.4
Cat B/Cat L 46.0 5.2 11.4 13.0 5.2 40.3
Cat L/Cat B 46.0 1.2 2.5 23.0 1.2 5.0
Cat B/Cat S 36.0 5.2 14.6 13.0 5.2 40.3
Cat S/Cat B 36.0 7.3 20.3 13.0 7.3 56.3
Cat L/Cat S 46.0 1.4 3.0 23.0 1.2 5.0
Cat S/Cat L 46.0 7.3 15.9 13.0 7.3 56.3
Cat K/Cat S 35.0 5.8 16.6 15.0 5.2 34.6
Cat S/Cat K 35.0 5.2 15.0 10.0 4.3 42.8
Thrombin/Factor Xa 91.0 26.5 29.1 42.0 26.4 63.0
Factor Xa/Thrombin 91.0 12.3 13.5 39.0 11.3 29.0
Trypsin/Factor Xa 63.0 12.3 19.5 15.0 9.0 60.0
Factor Xa/Trypsin 63.0 9.6 15.2 38.0 8.1 21.3
Trypsin/Thrombin 45.0 5.6 12.4 10.0 5.0 50.0
Thrombin/Trypsin 45.0 3.4 7.6 25.0 2.9 11.5
(a)
Table C.1: Search results for all fingerprints and selectivity sets. (a) – (e) report for each
fingerprint the average hit (HR) and recovery rates (RR) of pair–active (PAC ) and target–
selective (TSC ) compounds among the 100 top scoring database compounds. The maxHR
column reports the theoretically possible maximum hit rate for each selectivity set, given that
the number of potential hits in the background database is always smaller than 100.
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MOLPRINT 2D PAC [%] TSC [%]
maxHR HR RR maxHR HR RR
D1/D2 47.0 17.7 37.7 21.0 16.7 79.4
D2/D1 47.0 13.0 27.7 16.0 12.3 77.0
D1/D4 27.0 6.3 23.4 7.0 5.4 77.7
D4/D1 27.0 11.1 41.2 14.0 11.1 79.4
D2/D4 68.0 5.4 8.0 4.0 3.4 86.0
D4/D2 68.0 15.2 22.4 59.0 15.1 25.6
D3/D4 39.0 6.0 15.3 6.0 6.0 99.3
D4/D3 39.0 12.3 31.5 27.0 12.3 45.5
D2/5HT1a 29.0 5.3 18.3 5.0 4.3 86.4
5HT1a/D2 29.0 10.6 36.4 18.0 9.7 54.0
Alpha1/5HT1a 63.0 14.4 22.9 17.0 11.9 69.9
5HT1a/Alpha1 63.0 19.8 31.5 36.0 19.0 52.8
Cat B/Cat L 46.0 6.4 14.0 13.0 6.2 47.4
Cat L/Cat B 46.0 2.8 6.2 23.0 2.8 12.3
Cat B/Cat S 36.0 6.2 17.1 13.0 6.2 47.4
Cat S/Cat B 36.0 7.4 20.4 13.0 7.4 56.6
Cat L/Cat S 46.0 3.0 6.4 23.0 2.8 12.3
Cat S/Cat L 46.0 7.4 16.0 13.0 7.4 56.6
Cat K/Cat S 35.0 15.7 44.9 15.0 12.3 81.9
Cat S/Cat K 35.0 7.5 21.4 10.0 5.9 58.8
Thrombin/Factor Xa 91.0 27.3 30.0 42.0 27.3 65.0
Factor Xa/Thrombin 91.0 18.4 20.2 39.0 18.0 46.1
Trypsin/Factor Xa 63.0 11.0 17.5 15.0 10.0 66.9
Factor Xa/Trypsin 63.0 22.5 35.7 38.0 18.4 48.4
Trypsin/Thrombin 45.0 6.4 14.2 10.0 5.9 59.2
Thrombin/Trypsin 45.0 7.6 16.8 25.0 6.6 26.2
(b)
Table C.1: Continued.
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MP–MFP PAC [%] TSC [%]
maxHR HR RR maxHR HR RR
D1/D2 47.0 17.9 38.1 21.0 13.4 63.8
D2/D1 47.0 8.6 18.2 16.0 6.5 40.8
D1/D4 27.0 3.8 14.2 7.0 3.8 54.9
D4/D1 27.0 10.9 40.3 14.0 10.9 77.7
D2/D4 68.0 4.3 6.3 4.0 3.8 96.0
D4/D2 68.0 14.3 21.1 59.0 14.3 24.3
D3/D4 39.0 5.3 13.6 6.0 5.3 88.7
D4/D3 39.0 10.2 26.3 27.0 10.2 37.9
D2/5HT1a 29.0 4.2 14.3 5.0 4.2 83.2
5HT1a/D2 29.0 11.0 37.9 18.0 11.0 61.1
Alpha1/5HT1a 63.0 11.0 17.4 17.0 11.0 64.5
5HT1a/Alpha1 63.0 15.1 24.0 36.0 15.0 42.0
Cat B/Cat L 46.0 5.4 11.7 13.0 5.4 41.2
Cat L/Cat B 46.0 1.4 3.1 23.0 1.4 6.3
Cat B/Cat S 36.0 5.4 14.9 13.0 5.4 41.2
Cat S/Cat B 36.0 7.3 20.3 13.0 7.3 56.3
Cat L/Cat S 46.0 1.5 3.2 23.0 1.4 6.3
Cat S/Cat L 46.0 7.3 15.9 13.0 7.3 56.3
Cat K/Cat S 35.0 10.0 28.6 15.0 7.7 51.2
Cat S/Cat K 35.0 9.5 27.1 10.0 4.8 48.0
Thrombin/Factor Xa 91.0 26.1 28.7 42.0 26.0 62.0
Factor Xa/Thrombin 91.0 14.8 16.2 39.0 13.8 35.3
Trypsin/Factor Xa 63.0 9.8 15.6 15.0 8.8 58.4
Factor Xa/Trypsin 63.0 9.6 15.3 38.0 8.1 21.4
Trypsin/Thrombin 45.0 5.0 11.02 10.0 4.5 45.2
Thrombin/Trypsin 45.0 3.7 8.2 25.0 2.8 11.0
(c)
Table C.1: Continued.
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PDR–FP PAC [%] TSC [%]
maxHR HR RR maxHR HR RR
D1/D2 47.0 7.6 16.3 21.0 5.0 23.6
D2/D1 47.0 4.5 9.6 16.0 3.2 20.3
D1/D4 27.0 2.7 10.1 7.0 2.7 38.9
D4/D1 27.0 7.7 28.4 14.0 7.7 54.9
D2/D4 68.0 3.4 5.0 4.0 2.8 70.0
D4/D2 68.0 8.2 12.0 59.0 8.1 13.8
D3/D4 39.0 5.2 13.3 6.0 5.2 86.6
D4/D3 39.0 5.3 13.6 27.0 5.3 19.7
D2/5HT1a 29.0 3.9 13.5 5.0 3.9 78.4
5HT1a/D2 29.0 9.9 34.1 18.0 9.9 54.9
Alpha1/5HT1a 63.0 8.4 13.3 17.0 8.4 49.4
5HT1a/Alpha1 63.0 8.6 13.7 36.0 8.6 23.9
Cat B/Cat L 46.0 4.6 10.0 13.0 4.6 35.4
Cat L/Cat B 46.0 1.6 3.5 23.0 1.6 7.0
Cat B/Cat S 36.0 4.6 12.8 13.0 4.6 35.4
Cat S/Cat B 36.0 5.6 15.4 13.0 5.6 42.8
Cat L/Cat S 46.0 2.3 5.0 23.0 1.6 7.0
Cat S/Cat L 46.0 5.8 12.5 13.0 5.6 42.8
Cat K/Cat S 35.0 11.6 33.0 15.0 7.5 49.9
Cat S/Cat K 35.0 11.9 34.0 10.0 5.2 51.6
Thrombin/Factor Xa 91.0 26.3 28.9 42.0 23.2 55.2
Factor Xa/Thrombin 91.0 21.7 23.9 39.0 13.0 33.2
Trypsin/Factor Xa 63.0 19.9 31.6 15.0 12.9 86.1
Factor Xa/Trypsin 63.0 21.4 33.9 38.0 9.2 24.1
Trypsin/Thrombin 45.0 10.5 23.4 10.0 3.7 37.2
Thrombin/Trypsin 45.0 15.2 33.7 25.0 12.2 49.0
(d)
Table C.1: Continued.
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TGT PAC [%] TSC [%]
maxHR HR RR maxHR HR RR
D1/D2 47.0 14.0 29.8 21.0 10.2 48.8
D2/D1 47.0 5.5 11.7 16.0 4.8 30.0
D1/D4 27.0 3.0 11.0 7.0 3.0 42.3
D4/D1 27.0 9.0 33.5 14.0 9.0 64.6
D2/D4 68.0 5.3 7.8 4.0 3.2 80.0
D4/D2 68.0 10.5 15.4 59.0 10.3 17.5
D3/D4 39.0 3.0 7.8 6.0 3.0 50.6
D4/D3 39.0 9.0 23.3 27.0 9.0 33.6
D2/5HT1a 29.0 4.1 14.2 5.0 4.1 82.4
5HT1a/D2 29.0 9.0 30.9 18.0 9.0 49.8
Alpha1/5HT1a 63.0 8.2 13.1 17.0 8.2 48.5
5HT1a/Alpha1 63.0 14.6 23.2 36.0 14.6 40.6
Cat B/Cat L 46.0 6.4 14.0 13.0 6.4 49.6
Cat L/Cat B 46.0 1.2 2.6 23.0 1.2 5.2
Cat B/Cat S 36.0 6.4 17.9 13.0 6.4 49.5
Cat S/Cat B 36.0 6.3 17.6 13.0 6.3 48.6
Cat L/Cat S 46.0 2.3 5.0 23.0 1.2 5.2
Cat S/Cat L 46.0 6.3 13.7 13.0 6.3 48.6
Cat K/Cat S 35.0 12.9 36.8 15.0 7.8 51.7
Cat S/Cat K 35.0 7.3 21.0 10.0 5.0 50.0
Thrombin/Factor Xa 91.0 23.8 26.2 42.0 23.8 56.8
Factor Xa/Thrombin 91.0 10.2 11.2 39.0 10.0 25.6
Trypsin/Factor Xa 63.0 11.4 18.1 15.0 10.2 68.0
Factor Xa/Trypsin 63.0 14.1 22.3 38.0 13.9 36.5
Trypsin/Thrombin 45.0 5.6 12.5 10.0 4.0 39.6
Thrombin/Trypsin 45.0 4.4 9.8 25.0 4.0 15.8
(e)
Table C.1: Continued.
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C.2 Ward’s Clustering and DynaMAD
Level Size Small 5HT1a 5HT2a Alpha1 D1 D2 D3 D4 Purity [%]
0 267 0 53 21 26 33 25 37 72 27
1 157 0 34 17 3 7 22 0 64 41
110 19 4 23 16 3 37 8 34
2 54 0 1 4 0 14 8 0 27 50
103 33 13 3 3 14 0 37 36
24 0 0 3 1 0 20 0 83
86 19 4 20 15 3 17 8 23
3 26 0 1 1 0 0 0 0 24 92
28 0 3 0 14 8 0 3 50
50 17 7 2 0 10 0 14 34
53 16 6 1 3 4 0 23 43
16 0 0 3 1 0 12 0 75
8 0 0 0 0 0 8 0 100
49 16 3 2 12 2 7 7 33
37 3 1 18 3 1 10 1 49
4 10 1 1 0 0 0 0 0 9 90
16 0 1 0 0 0 0 15 94
9 0 2 0 2 2 0 3 33
19 0 1 0 12 6 0 0 63
18 3 4 1 0 7 0 3 39
32 14 3 1 0 3 0 11 44
32 10 4 1 3 4 0 10 31
21 6 2 0 0 0 0 13 62
6 0 0 2 0 0 4 0 67
6 0 0 1 0 0 5 0 83
5 0 0 0 0 0 5 0 100
25 10 3 0 6 2 0 4 40
16 6 0 1 0 0 7 2 44
7 0 0 3 1 0 3 0 43
10 0 1 7 0 1 1 0 70
5 10 4 1 0 0 0 0 0 9 90
16 0 1 0 0 0 0 15 94
9 0 2 0 2 2 0 3 33
9 0 0 0 7 2 0 0 78
7 0 0 0 4 3 0 0 57
18 3 4 1 0 7 0 3 39
14 2 0 1 0 3 0 8 57
7 4 3 0 0 0 0 0 57
8 8 0 0 0 0 0 0 100
7 0 0 1 3 3 0 0 43
6 6 0 0 0 0 0 0 100
19 4 4 0 0 1 0 10 53
4 0 1 0 0 0 0 3 75
17 6 1 0 0 0 0 10 59
6 0 0 2 0 0 4 0 67
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Table C.2 – continued from previous page
Level Size Small 5HT1a 5HT2a Alpha1 D1 D2 D3 D4 Purity [%]
4 0 0 0 1 0 3 0 75
6 0 0 1 0 0 5 0 83
5 0 0 0 0 0 5 0 100
7 0 0 0 5 0 0 2 71
6 3 3 0 0 0 0 0 50
2 7 0 0 1 2 0 2 58
8 0 0 1 6 0 0 1 75
13 4 0 0 0 0 7 2 54
9 0 0 7 0 0 2 0 78
7 0 0 3 1 0 3 0 43
10 0 1 7 0 1 1 0 70
4 0 0 0 0 0 4 0 100
7 3 0 1 2 0 0 1 43
Table C.2: Results of Ward’s clustering. Level gives the clustering level in the
cluster tree, and Size is the number of compounds in each cluster. Small reports the
number of clusters containing one to three compounds. Purity gives the percentage
of compounds of the most frequently occurring selectivity set in each cluster.
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DEL Descr TSC FSC ZINC HR [%] RR [%]
5HT1a
0 0.2 26.0 198.4 3 114 327.1 0.0 96.4
1 2.8 22.5 70.2 134 494.4 0.0 83.3
2 5.4 20.2 35.6 7 372.5 0.3 75.0
3 7.6 18.6 29.2 4 991.2 0.4 68.9
4 13.0 16.0 10.8 1 898.8 0.8 59.1
5 20.5 14.0 3.8 737.4 1.8 51.7
6 28.9 12.0 0.6 300.4 3.8 44.3
7 34.1 10.9 0.1 149.8 6.8 40.4
8 40.4 9.4 0.1 111.9 7.8 35.0
9 47.6 8.5 0.1 85.4 9.0 31.4
10 54.8 7.8 0.1 58.2 11.8 28.9
11 68.4 7.0 0.1 29.3 19.3 26.1
12 79.6 6.4 0.1 8.8 41.7 23.6
13 92.5 5.8 0.1 6.0 48.5 21.3
14 105.2 5.1 0.1 3.8 56.9 19.0
15 115.8 4.6 0.1 2.8 61.2 17.0
16 126.1 4.6 0.1 2.6 63.5 17.0
17 131.8 4.6 0.1 2.3 66.1 17.0
18 144.6 4.4 0.1 2.3 65.1 16.3
19 155.0 4.2 0.1 2.3 64.0 15.6
5HT2a
0 0.9 9.0 130.7 1 512 766.0 0.0 81.8
1 3.7 6.0 32.9 23 970.9 0.0 54.2
2 8.6 4.9 3.0 2 515.4 0.2 44.4
3 12.4 4.2 0.4 792.4 0.5 37.8
4 15.0 3.6 0.4 719.1 0.5 32.7
5 18.9 3.2 0.2 308.6 1.0 28.7
6 25.8 2.4 0.0 26.3 8.2 21.5
7 31.7 1.5 0.0 10.0 13.2 13.8
8 37.0 1.2 0.0 3.3 26.8 10.9
9 47.5 0.8 0.0 0.6 55.6 7.3
10 56.2 0.6 0.0 0.2 80.0 5.8
11 66.6 0.5 0.0 0.1 86.7 4.7
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Table C.3 – continued from previous page
DEL Descr TSC FSC ZINC HR [%] RR [%]
12 79.1 0.3 0.0 0.0 88.9 2.9
13 90.6 0.3 0.0 0.0 88.9 2.9
14 101.8 0.2 0.0 0.0 85.7 2.2
15 113.4 0.1 0.0 0.0 100.0 1.1
16 120.9 0.1 0.0 0.0 100.0 1.1
17 129.8 0.1 0.0 0.0 100.0 1.1
18 142.4 0.1 0.0 0.0 100.0 1.1
19 155.0 0.1 0.0 0.0 100.0 1.1
Alpha1
0 1.0 11.0 159.6 1 960 117.4 0.0 84.9
1 6.3 8.2 5.3 4 162.7 0.2 62.8
2 9.2 6.8 3.4 1 366.5 0.5 52.6
3 11.8 6.0 2.3 1 100.4 0.5 46.5
4 17.4 4.8 0.8 258.1 1.8 36.6
5 24.4 3.6 0.0 66.0 5.2 28.0
6 33.7 2.7 0.0 25.7 9.6 20.9
7 45.7 2.1 0.0 11.6 15.2 16.0
8 55.4 2.0 0.0 8.4 18.9 15.1
9 67.3 1.9 0.0 2.0 48.5 14.5
10 72.9 1.8 0.0 1.0 63.9 14.2
11 84.4 1.8 0.0 0.5 9.3 14.2
12 93.6 1.8 0.0 0.5 78.9 13.9
13 101.5 1.7 0.0 0.5 78.2 13.2
14 109.7 1.6 0.0 0.4 78.8 12.6
15 120.7 1.6 0.0 0.4 80.0 12.3
16 128.0 1.6 0.0 0.4 80.0 12.3
17 132.0 1.6 0.0 0.4 80.0 12.3
18 144.3 1.6 0.0 0.4 80.0 12.3
19 155.0 1.6 0.0 0.4 80.0 12.3
D1
0 0.1 16.4 219.8 3 400 431.7 0.0 96.2
1 1.8 13.7 107.0 199 947.8 0.0 80.5
2 4.4 11.8 63.7 21 176.2 0.1 69.7
Table C.3 – continued on next page
APPENDIX C. CALCULATION DATA 167
Table C.3 – continued from previous page
DEL Descr TSC FSC ZINC HR [%] RR [%]
3 7.7 10.1 21.1 5 311.1 0.2 59.5
4 10.6 9.8 10.5 702.2 1.4 57.4
5 12.2 9.1 5.1 383.3 2.3 53.4
6 17.3 8.6 2.3 106.5 7.3 50.4
7 20.7 7.8 1.5 77.6 9.0 45.9
8 26.1 6.7 0.8 28.8 18.5 39.3
9 32.3 5.8 0.2 7.4 43.2 34.4
10 37.7 4.5 0.0 2.4 64.4 26.4
11 47.3 3.7 0.0 1.2 74.8 21.7
12 58.0 2.9 0.0 0.5 84.7 16.9
13 68.0 2.5 0.0 0.2 91.3 14.8
14 82.6 2.4 0.0 0.2 92.3 14.1
15 100.4 2.4 0.0 0.2 92.2 13.9
16 112.9 2.3 0.0 0.2 92.1 13.7
17 128.4 2.3 0.0 0.2 92.1 13.7
18 139.7 2.3 0.0 0.2 92.1 13.7
19 155.0 2.3 0.0 0.2 92.1 13.7
D2
0 1.0 11.1 78.8 105 315.0 0.0 85.2
1 3.7 8.4 50.9 3 102.7 0.3 64.3
2 6.9 6.0 23.6 647.4 0.9 46.5
3 10.1 5.2 22.3 436.4 1.1 39.7
4 13.0 4.9 17.2 239.5 1.9 37.9
5 14.2 4.5 14.8 196.6 2.1 34.5
6 17.7 3.9 8.9 48.9 6.4 30.2
7 27.9 2.8 3.1 26.6 8.5 21.2
8 32.6 2.6 2.4 18.4 10.9 19.7
9 39.1 2.1 1.8 9.9 15.4 16.3
10 49.8 1.8 0.4 1.1 55.6 13.9
11 59.4 1.8 0.0 1.0 63.8 13.5
12 71.6 1.6 0.0 0.2 87.2 12.6
13 83.5 1.4 0.0 0.0 97.2 10.8
14 97.5 1.2 0.0 0.0 100.0 8.9
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Table C.3 – continued from previous page
DEL Descr TSC FSC ZINC HR [%] RR [%]
15 110.3 1.1 0.0 0.0 100.0 8.3
16 121.5 1.1 0.0 0.0 100.0 8.3
17 129.9 1.0 0.0 0.0 100.0 7.7
18 143.1 0.8 0.0 0.0 100.0 6.5
19 155.0 0.8 0.0 0.0 100.0 6.2
D3
0 6.6 10.7 9.1 2 254.6 0.5 56.2
1 23.3 8.0 5.4 24.4 21.1 41.9
2 36.4 6.8 3.2 19.4 23.2 36.0
3 45.6 4.6 2.8 6.3 33.7 24.4
4 52.0 4.3 1.8 4.2 41.9 22.7
5 55.8 4.1 0.8 2.5 55.1 21.5
6 57.9 4.0 0.8 2.2 57.1 21.3
7 61.4 3.6 0.0 0.2 95.7 18.7
8 65.6 2.6 0.0 0.0 98.5 13.5
9 70.4 2.0 0.0 0.0 100.0 10.7
10 76.3 1.7 0.0 0.0 100.0 9.1
11 82.2 1.7 0.0 0.0 100.0 8.8
12 89.0 1.7 0.0 0.0 100.0 8.8
13 94.4 1.7 0.0 0.0 100.0 8.8
14 101.9 1.4 0.0 0.0 100.0 7.4
15 112.2 1.2 0.0 0.0 100.0 6.3
16 122.2 0.9 0.0 0.0 100.0 4.6
17 132.0 0.9 0.0 0.0 100.0 4.6
18 42.6 0.9 0.0 0.0 100.0 4.6
19 155.0 0.8 0.0 0.0 100.0 4.4
D4
0 0.0 36.0 195.0 3 684 443.0 0.0 100.0
1 0.4 34.6 147.8 2 472 909.9 0.0 96.0
2 2.2 31.5 81.9 437 082.9 0.0 87.4
3 4.7 29.5 64.5 33 396.5 0.1 81.9
4 8.9 28.0 19.9 9 112.9 0.3 77.9
5 10.2 27.3 14.7 7 277.4 0.4 75.8
Table C.3 – continued on next page
APPENDIX C. CALCULATION DATA 169
Table C.3 – continued from previous page
DEL Descr TSC FSC ZINC HR [%] RR [%]
6 14.3 26.2 9.3 4 042.6 0.6 72.7
7 17.4 24.5 7.2 2 399.8 1.0 68.0
8 22.0 22.5 4.2 1 562.9 1.4 62.6
9 27.7 20.7 3.0 471.1 4.2 57.4
10 34.1 18.3 2.8 288.4 5.9 50.9
11 44.5 16.6 2.2 168.2 8.9 46.2
12 60.2 14.8 1.5 105.2 12.2 41.2
13 71.9 14.0 1.5 89.9 13.2 38.8
14 90.1 12.5 1.0 61.8 16.6 34.8
15 107.2 11.4 0.9 47.4 19.1 31.7
16 123.6 10.4 0.7 39.0 20.8 28.9
17 129.2 9.7 0.7 33.9 21.9 27.0
18 143.5 9.6 0.7 28.7 24.7 26.8
19 155.0 9.5 0.7 28.0 24.9 26.4
Table C.3: Average DynaMAD results over all dimension extension levels and
selectivity sets. Results are reported for all dimension extension levels (DEL). Rows
with dimension extension levels producing fewer than 100 compounds are given in
bold. Descr reports the number of descriptors at the corresponding DEL, which is
equivalent to the dimensionality of the chemical reference space at that mapping step.
TSC and FSC stand for target– and family–selective compounds, respectively. Hit
and recovery rates are calculated for target–selective compounds.
